Podcasts about new england journal

Today, I'm joined by Dr. Lisa Shah, Chief Medical Officer at Twin Health.   Replacing population averages with personal biomarkers, Twin Health leverages digital twin technology to address root causes of metabolic conditions like obesity and diabetes.   In this episode, we discuss how machine learning is transforming disease management.   We also cover:   Building a GLP-1 off-ramp Balancing AI with human support Achieving a 71% diabetes reversal rate   Subscribe to the podcast → insider.fitt.co/podcast  Subscribe to our newsletter → insider.fitt.co/subscribe  Follow us on LinkedIn → linkedin.com/company/fittinsider    Twin Health's Website: www.twinhealth.com  Dr. Lisa Shah's LinkedIn: https://www.linkedin.com/in/lisa-shah-4a297b19/ Twin Health's Facebook: https://www.facebook.com/twinhealthusa/ Twin Health's Instagram: https://www.instagram.com/twinhealthusa Twin Health's LinkedIn: https://www.linkedin.com/company/twinhealth/   -   The Fitt Insider Podcast is brought to you by EGYM. Visit EGYM.com  to learn more about its smart workout solutions for fitness and health facilities.   Fitt Talent: https://talent.fitt.co/  Consulting: https://consulting.fitt.co/  Investments: https://capital.fitt.co/    Chapters: (00:00) Introduction (02:00) Digital twin technology explained and healthcare applications (04:15) Why digital twin technology is finally possible now (08:30) Turning 3K daily data points into actionable guidance (11:15) Balancing digital twin AI with human care team support (15:00) Clinical outcomes and New England Journal of Medicine study (19:15) Root cause solutions vs symptom management (21:15) Scaling from employer benefits to consumer prevention (24:00) Value-based care approach vs. direct-to-consumer model (27:15) Digital twin complexity across multiple health systems (31:00) Building trust through real-time feedback loops (33:00) Agentic AI applications in healthcare delivery (37:42) Future roadmap (40:15) Conclusion  

Sasha K. Shillcutt, MD, MS, FASE is a tenured and endowed Professor and the Vice Chair of Strategy in the Department of Anesthesiology at the University of Nebraska Medical Center. She is a double-boarded cardiac anesthesiologist and is also CEO & Founder of Brave Enough, a community of thousands of women in healthcare where she teaches women how to advance through courses, coaching, and events. She leads conferences and retreats for professional women and is a certified coach for women leaders. Sasha is a well-published researcher in anesthesiology and gender equity, best-selling author, and international speaker. She speaks frequently to executives and leaders on the topics of professional resilience and wellbeing. Her TEDx talk titled Resilience: The Art of Failing Forward has been viewed by thousands of people. Her writing has been published in both the New England Journal of Medicine and JAMA. Her first book, Between Grit and Grace: How to be Feminine and Formidable, has sold thousands of copies and her second book, Brave Boundaries, is an international best seller. Her podcast, The Brave Enough Show, has over 315K downloads & she has coached hundreds of women leaders to thrive. Some of the topics we discussed were:Taking care of everybody else without leaving room for yourselfPrioritizing your well-being by setting aside time just for youHow to set up boundariesWhat boundaries really areSetting up boundaries in your personal life (like with your partner, children, parents, siblings, friends, etc.)Communicating your boundaries with othersSetting up boundaries at workAnd more!Learn more about me or schedule a FREE coaching call:https://www.joyfulsuccessliving.com/Join the Voices of Women Physicians Facebook Group:https://www.facebook.com/groups/190596326343825/ Connect with Dr. Shilcutt: WEBSITEINSTAGRAMFACEBOOKTWITTERLINKEDIN 

Send us a message with this link, we would love to hear from you. Standard message rates may apply. We unpack myths, the new stepwise approach, and why return to school should come before return to play.• what a concussion is• common and delayed symptoms including mood and sleep changes• immediate sideline steps• why “cocooning” is outdated and how light activity helps• individualized recovery timelines and risk of returning too soon• return-to-learn before return-to-play with simple accommodations• a staircase model for activity and symptom thresholds• helmets vs brain movement and the role of honest reporting• practical tips for coaches, parents, and student athletesCheck out our website, send us an email, share this with a friend or young student athlete who is playing some sports and might get a concussionReferencesBroglio SP, Register-Mihalik JK, Guskiewicz KM, et al. National Athletic Trainers' Association Bridge Statement: Management of Sport-Related Concussion. Journal of Athletic Training. 2024;59(3):225-242. doi:10.4085/1062-6050-0046.22.Centers for Disease Control and Prevention Guideline on the Diagnosis and Management of Mild Traumatic Brain Injury Among Children. Lumba-Brown A, Yeates KO, Sarmiento K, et al. JAMA Pediatrics. 2018;172(11):e182853. doi:10.1001/jamapediatrics.2018.2853.Feiss R, Lutz M, Reiche E, Moody J, Pangelinan M. A Systematic Review of the Effectiveness of Concussion Education Programs for Coaches and Parents of Youth Athletes. International Journal of Environmental Research and Public Health. 2020;17(8):E2665. doi:10.3390/ijerph17082665.Gereige RS, Gross T, Jastaniah E. Individual Medical Emergencies Occurring at School. Pediatrics. 2022;150(1):e2022057987. doi:10.1542/peds.2022-057987.Giza CC, Kutcher JS, Ashwal S, et al. Summary of Evidence-Based Guideline Update: Evaluation and Management of Concussion in Sports: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;80(24):2250-2257. doi:10.1212/WNL.0b013e31828d57dd.Halstead ME. What's New With Pediatric Sport Concussions? Pediatrics. 2024;153(1):e2023063881. doi:10.1542/peds.2023-063881.Halstead ME, Walter KD, Moffatt K. Sport-Related Concussion in Children and Adolescents. Pediatrics. 2018;142(6):e20183074. doi:10.1542/peds.2018-3074.Leddy JJ. Sport-Related Concussion. The New England Journal of Medicine. 2025;392(5):483-493. doi:10.1056/NEJMcp2400691.McCrea M, Broglio S, McAllister T, et al. Return to Play and Risk of Repeat Concussion in Collegiate Football Players: Comparative Analysis From the NCAA Concussion Study (1999–2001) and CARE Consortium (2014–2017). British Journal of Sports Medicine. 2020;54(2):102-109. doi:10.1136/bjsports-2019-100579.Scorza KA, Cole W. Current Concepts in Concussion: Initial Evaluation and Management. American Family Physician. 2019;99(7):426-434.Shirley E, Hudspeth LJ, Maynard JR. Managing Sports-Related Concussions From Time of Injury Through Return to Play. The Journal of the American Academy of Orthopaedic Surgeons. 2018;26(13):e279-e286. doi:10.5435/JAAOS-D-16-00684.Zhou H, Ledsky R, Sarmiento K, et al. Parent-Child Communication About ConcussSupport the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

Is your smartwatch just a fun gadget, or a serious medical device?  In this episode, Jonathan Wolf is joined by Dr. Malcolm Findlay, a leading consultant cardiologist, to explore the powerful health data available on your wrist. They decode the most misunderstood metric, Heart Rate Variability (HRV), and reveal how your wearable can provide clinical-grade insights into your heart's health. Dr. Findlay explains the counter-intuitive science behind HRV — why more ‘wobble' in your heartbeat is a sign of good health — and breaks down the two opposing nervous systems that control it. He shares the latest on how these devices can accurately detect serious conditions like atrial fibrillation and why he, as a cardiologist, trusts the ECG function on a consumer smartwatch to make diagnoses. For listeners who track their own data, this episode is a practical guide to what your numbers actually mean. Dr. Findlay explains how to interpret your personal HRV trends, what constitutes a significant change, and when you should use the ECG feature. He also debunks common myths about heart rate zones, revealing the level of exercise intensity that truly benefits your long-term health. The episode concludes with an empowering look at how this technology is shifting control into our own hands. Can a simple alert from your watch really help prevent a catastrophic event like a stroke? Discover which metrics matter most and how to use them to guide your wellness journey.

In this episode of Quah (Q & A), Sal, Adam & Justin coach four Pump Heads via Zoom. Mind Pump Fit Tip: 6 Ways to Destroy Your Testosterone. (2:38) Classic bad dad mistake. (26:56) The dangers of daily plastic exposure for kids. (29:45) Net positive or negative with these GLP-1 weight-loss drugs. (35:13) The more you know. (38:40) Shout out to @mdmotivator on Instagram. (42:01) Stay hydrated out there! (44:06) Billionaire chat.  (46:01) The grass-fed market is exploding! (51:23) #ListenerLive question #1 – Do you have any go-to methods or overlooked strategies for improving grip strength in the general population clients? (53:24) #ListenerLive question #2 – I am starting to get bored in the gym and want a new workout routine to switch things up.  Can you point me in the direction of something that would challenge me and still be fun for me to do? (1:03:37) #ListenerLive question #3 – I'd love to follow up on your first round of advice and get your guidance on breaking through this plateau so I actually look different next year. (1:12:18) #ListenerLive question #4 – Any advice on how I should train when I've been dealing with a chronic injury? (1:23:01) Related Links/Products Mentioned Ask a question to Mind Pump, live! Email: live@mindpumpmedia.com Get your free Sample Pack with any “drink mix” purchase! Find your favorite LMNT flavor or share it with a friend. Try LMNT risk-free. If you don't like it, give it away to a salty friend and we'll give you your money back, no questions asked! Visit DrinkLMNT.com/MindPump Visit Butcher Box for this month's exclusive Mind Pump offer!  ** Available for a limited time, a curated box pre-filled with Mind Pump's favorite cuts — no guesswork! Butcher Box members who sign up through Mind Pump will receive: $20 OFF their first box, Free chicken breast, ground beef, OR salmon in every box for a whole year! ** Flash Sale: MAPS Performance 50% off! ** Code ATHLETE50 at checkout. ** Mind Pump Store The Link Between Sleep and Testosterone Effect of partial and total sleep deprivation on serum testosterone in healthy males: a systematic review and meta-analysis Examining the effects of calorie restriction on testosterone concentrations in men: a systematic review and meta-analysis Mind Pump #2690: The NEW DIET Everyone Is Using For Fat Loss How a sedentary lifestyle reduces testosterone levels in men Correlation between serum zinc and testosterone Cortisol and testosterone dynamics following exhaustive endurance exercise Childhood plastic exposure could be fueling obesity, infertility, and asthma Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine Ozempic's hidden pregnancy risk few women know about A Runner Shattered the Stroller Mile World Record Baby strollers for Rolls-Royce Cullinan In Memoriam: The 31 Billionaires Who Died Over The Past Year Visit Luminose by Entera for an exclusive offer for Mind Pump listeners! ** Promo code MPM at checkout for 10% off their order or 10% off their first month of a subscribe-and-save. ** Mind Pump #2659: Eight Ways to Build a Crushing Grip & Strong Forearms & More (Listener Live Coaching) MAPS Prime Pro Webinar Trainer Bonus Series Episode 3: Assessments That Sell Training Mind Pump Podcast – YouTube Mind Pump Free Resources People Mentioned

Welcome to Ozempic Weightloss Unlocked, where we dive into the latest breakthroughs and controversies surrounding Ozempic, its medical use, and its impact on everyday wellness.The big headline this month is the arrival of a new pill form of semaglutide, the main ingredient in Ozempic. According to The New England Journal of Medicine, people who took this daily pill lost almost 14 percent of their body weight over 64 weeks, compared to just 2 percent for those on a placebo. Fifty percent of the patients shed at least 15 percent of their weight, with nearly a third losing 20 percent or more. Novo Nordisk, the company that makes Ozempic, announced even stronger results for those who stuck to their treatment plan, with close to 17 percent average weight loss. This pill, pending approval, could be a game changer for people who prefer not to take injections.On the injectable front, clinical trials featured in The Lancet indicate that a higher 7.2 milligram weekly dose of semaglutide in adults without diabetes led to almost 19 percent average weight loss, higher than what's seen with lower doses. These numbers highlight ongoing efforts to increase the effectiveness of Ozempic for those struggling with obesity.Yet, it's crucial to balance these promising results with real-world insights. The Mayo Clinic and NYU Langone Health recently compared Ozempic's results to traditional weight loss surgery, like gastric bypass and sleeve gastrectomy. Their research revealed that surgery is five times more effective than GLP-1 drugs such as Ozempic, with surgical patients losing an average of 58 pounds after two years versus just 12 pounds for those on the drug for six months. Experts also noted that only 30 percent of patients stick with GLP-1 drugs for longer than a year, and real-world weight loss may be lower than trial results suggest. Surgery, however, isn't without its risks, including potential infections, blood clots, and hernias, and requires strict diet and lifestyle changes afterward.Turning to genetics, Cleveland Clinic research shows that the effectiveness of Ozempic may depend on your DNA. A specific variant in the Neurobeachin gene seems to make some people much more responsive to these medications, leading to 82 percent higher odds of substantial weight loss. This new insight could help doctors tailor treatments so patients get therapies most suited to their genetic profile.Lifestyle stakes are high, and so are concerns about side effects and safety. Recent studies report that Ozempic may cause severe conditions such as gastroparesis, bowel blockages, pancreatic and kidney injuries, and vision problems. Even hair loss is emerging as a potentially significant side effect, especially for women—according to recent findings, female users experienced about twice the rate of hair loss compared to those not using Ozempic.Because of these risks, there are currently over two thousand active lawsuits against Novo Nordisk and other GLP-1 manufacturers, with ongoing multidistrict litigation. These lawsuits allege that the companies did not give enough warning about the dangers, and some patients claim life-changing or life-threatening complications.Compounded GLP-1 drugs, made in pharmacies rather than by pharmaceutical companies, became popular when Ozempic was in short supply. However, the FDA warns that compounded drugs can be risky because they're not evaluated for safety or effectiveness. While the shortage has officially ended, compounded formulations remain in circulation.If you are considering Ozempic—whether as a pill, injection, or a compounded version—talk with your healthcare provider and review your health history, genetic background, and lifestyle goals. Widespread interest has led to changing availability, promising new forms, and more transparent labeling, especially after recent updates about kidney and pancreatic risks.To sum up, Ozempic continues to make waves as both a treatment for diabetes and a potent tool for weight loss. With fresh news about new pill forms, higher effective doses, genetic influences, and ongoing legal cases, it's important to stay informed and make choices based on both science and your personal health needs.Thanks for tuning in to Ozempic Weightloss Unlocked. Don't forget to subscribe to stay up to date on the latest developments. This has been a Quiet Please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

These diseases - West Nile Virus, Lyme disease, and Rocky Mountain Spotted Fever - are named for the places where outbreaks happened. But they're also all things you get from being bitten by mosquitoes or ticks. Research: Balasubramanian, Chandana. “Rocky Mountain Spotted Fever (RMSF): The Deadly Tick-borne Disease That Inspired a Hit Movie.” Gideon. 9/1/2022. https://www.gideononline.com/blogs/rocky-mountain-spotted-fever/ Barbour AG, Benach JL2019.Discovery of the Lyme Disease Agent. mBio10:10.1128/mbio.02166-19.https://doi.org/10.1128/mbio.02166-19 Bay Area Lyme Foundation. “History of Lyme Disease.” https://www.bayarealyme.org/about-lyme/history-lyme-disease/ Caccone, Adalgisa. “Ancient History of Lyme Disease in North America Revealed with Bacterial Genomes.” Yale School of Medicine. 8/28/2017. https://medicine.yale.edu/news-article/ancient-history-of-lyme-disease-in-north-america-revealed-with-bacterial-genomes/ Chowning, William M. “Studies in Pyroplasmosis Hominis.("Spotted Fever" or "Tick Fever" of the Rocky Mountains.).” The Journal of Infectious Diseases. 1/2/1904. https://archive.org/details/jstor-30071629/page/n29/mode/1up Elbaum-Garfinkle, Shana. “Close to home: a history of Yale and Lyme disease.” The Yale journal of biology and medicine vol. 84,2 (2011): 103-8. Farris, Debbie. “Lyme disease older than human race.” Oregon State University. 5/29/2014. https://science.oregonstate.edu/IMPACT/2014/05/lyme-disease-older-than-human-race Galef, Julia. “Iceman Was a Medical Mess.” Science. 2/29/2012. https://www.science.org/content/article/iceman-was-medical-mess Gould, Carolyn V. “Combating West Nile Virus Disease — Time to Revisit Vaccination.” New England Journal of Medicine. Vol. 388, No. 18. 4/29/2023. https://www.nejm.org/doi/full/10.1056/NEJMp2301816 Harmon, Jim. “Harmon’s Histories: Montana’s Early Tick Fever Research Drew Protests, Violence.” Missoula Current. 7/20/2020. https://missoulacurrent.com/ticks/ Hayes, Curtis G. “West Nile Virus: Uganda, 1937, to New York City, 1999.” From West Nile Virus: Detection, Surveillance, and Control. New York : New York Academy of Sciences. 2001. https://archive.org/details/westnilevirusdet0951unse/ Jannotta, Sepp. “Robert Cooley.” Montana State University. 10/12/2012. https://www.montana.edu/news/mountainsandminds/article.html?id=11471 Johnston, B L, and J M Conly. “West Nile virus - where did it come from and where might it go?.” The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses vol. 11,4 (2000): 175-8. doi:10.1155/2000/856598 Lloyd, Douglas S. “Circular Letter #12 -32.” 8/3/1976. https://portal.ct.gov/-/media/departments-and-agencies/dph/dph/infectious_diseases/lyme/1976circularletterpdf.pdf Mahajan, Vikram K. “Lyme Disease: An Overview.” Indian dermatology online journal vol. 14,5 594-604. 23 Feb. 2023, doi:10.4103/idoj.idoj_418_22 MedLine Plus. “West Nile virus infection.” https://medlineplus.gov/ency/article/007186.htm National Institute of Allergy and Infectious Disease. “History of Rocky Mountain Labs (RML).” 8/16/2023. https://www.niaid.nih.gov/about/rocky-mountain-history National Institute of Allergy and Infectious Disease. “Rocky Mountain Spotted Fever.” https://www.niaid.nih.gov/diseases-conditions/rocky-mountain-spotted-fever Rensberger, Boyce. “A New Type of Arthritis Found in Lyme.” New York Times. 7/18/1976. https://www.nytimes.com/1976/07/18/archives/a-new-type-of-arthritis-found-in-lyme-new-form-of-arthritis-is.html?login=smartlock&auth=login-smartlock Rucker, William Colby. “Rocky Mountain Spotted Fever.” Washington: Government Printing Office. 1912. https://archive.org/details/101688739.nlm.nih.gov/page/ Sejvar, James J. “West Nile virus: an historical overview.” Ochsner journal vol. 5,3 (2003): 6-10. https://pmc.ncbi.nlm.nih.gov/articles/PMC3111838/ Smithburn, K.C. et al. “A Neurotropic Virus Isolated from the Blood of a Native of Uganda.” The American Journal of Tropical Medicine and Hygiene. Volume s1-20: Issue 4. 1940. Steere, Allen C et al. “The emergence of Lyme disease.” The Journal of clinical investigation vol. 113,8 (2004): 1093-101. doi:10.1172/JCI21681 Steere, Allen C. et al. “Historical Perspectives.” Zbl. Bakt. Hyg. A 263, 3-6 (1986 ). https://pdf.sciencedirectassets.com/281837/1-s2.0-S0176672486X80912/1-s2.0-S0176672486800931/main.pdf World Health Organization. “West Nile Virus.” 10/3/2017. https://www.who.int/news-room/fact-sheets/detail/west-nile-virus Xiao, Y., Beare, P.A., Best, S.M. et al. Genetic sequencing of a 1944 Rocky Mountain spotted fever vaccine. Sci Rep 13, 4687 (2023). https://doi.org/10.1038/s41598-023-31894-0 See omnystudio.com/listener for privacy information.

Welcome back, listeners, to Ozempic Weightloss Unlocked. Today, we are uncovering the latest news and updates on Ozempic, from its medical applications to its influence on our daily lives and overall health.There is an exciting development in the world of weight loss medication: a pill form of Ozempic, known by its generic name semaglutide. According to The New England Journal of Medicine, those who took the daily semaglutide pill lost nearly fourteen percent of their body weight over sixty-four weeks, compared to just two percent for those who took a placebo. This makes oral semaglutide a potential game changer for those who prefer pills over injections, especially since the pill shows a safety profile similar to the injectable form. Dr. Sean Wharton, who led the recent clinical trial, explained that this oral option could greatly expand the number of people willing to try GLP-1 treatments for obesity.Following closely behind is orforglipron, a new GLP-1 pill developed by Eli Lilly. Fox News reports that in a recent clinical trial, participants taking the highest dose of orforglipron lost an average of more than twenty-seven pounds after a year and a half. Nearly sixty percent of those participants lost ten percent of their body weight, while just under forty percent lost at least fifteen percent. What is even more hopeful, according to the study published in The New England Journal of Medicine, is that those with pre-diabetes saw a sharp improvement in blood sugar levels, suggesting broad metabolic benefits. While the results are compelling, experts note that injectables like Ozempic still deliver slightly more dramatic results, yet many patients may prefer the convenience and ease of a pill.On a different front, research from The Cleveland Clinic has revealed that genetics may influence just how well Ozempic or similar drugs work for you. According to their study, a gene known as Neurobeachin appears to help determine how much weight a person might lose with GLP-1 medications. People with a responsive version of the gene were eighty-two percent more likely to have significant weight loss, while those with a non-responsive score were actually less likely to lose weight. Dr. Daniel Rotroff from the Cleveland Clinic suggests that in the near future, doctors could combine genetic testing with lifestyle and personal factors to tailor obesity treatment, making these therapies even more effective and personalized.Let us not forget the reason why Ozempic was developed in the first place. Originally designed and approved to help manage type two diabetes, Ozempic as well as its higher-dose sibling Wegovy, are now also used for chronic weight management. Both are part of a class called glucagon-like peptide-1 receptor agonists, or GLP-1s. These medications work by stimulating insulin production and helping the body manage appetite and digestion, leading to weight loss as a beneficial side effect. According to information from the Lawsuit Information Center, Ozempic is still mainly prescribed as a once-weekly injection, but with oral versions nearing approval, that could soon change.New treatments often come with questions about safety. According to the United States Food and Drug Administration, there has been increased concern about unapproved compounded versions of these GLP-1 drugs, which have been linked to hundreds of adverse event reports. This highlights the importance of using only medications that are properly prescribed and approved, as safety must always come first.Finally, there are ongoing investigations into rare but serious side effects, such as a risk of vision loss, and digestive issues like gastroparesis linked to GLP-1 drugs including Ozempic. For most people, side effects tend to be mild and include nausea and digestive discomfort, but it is crucial to talk to your doctor to understand the potential risks and benefits as this new generation of weight loss options emerges.That wraps up our update on Ozempic and the evolving world of GLP-1 weight loss therapies. Thanks for tuning in to Ozempic Weightloss Unlocked. Do not forget to subscribe for more insights, and as always, stay informed and stay healthy. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Multiple food allergies are a daily stressor for millions of families. From avoiding social events to fearing accidental exposures, it can feel like living in a constant state of alert. Until recently, there were no FDA-approved treatments that targeted more than one allergen at a time. In this episode, we break down the study: “Omalizumab for the Treatment of Multiple Food Allergies,” published in 2024 in the New England Journal of Medicine. Known as the OUtMATCH trial, it's the first large-scale study to show that omalizumab (Xolair), a biologic already used for asthma and hives, may help people with multiple food allergies by raising the threshold for reactions. We explain how omalizumab works by blocking IgE, the antibody that triggers allergic reactions, and how the study measured changes in reaction thresholds (the amount of an allergen a person can ingest before reacting). We also explore the trial design, results, safety profile, and what all of this means for the day-to-day management of food allergies. What we cover in our episode about OUtMATCH trial How omalizumab works to prevent allergic reactions: Learn how blocking IgE increases the amount of allergen needed to trigger symptoms, offering protection from small, accidental exposures. Who qualified for the OUtMATCH trial and why: Find out which patients were included and how eligibility impacted outcomes. What success looked like in this study: Understand how researchers defined protection across multiple allergens. Why not everyone responded the same to omalizumab: Explore the variability in results and what it means for clinical care. What else the study found beyond food challenges: Hear about safety findings, quality of life data, and the open-label extension.

Welcome to The Peptide Podcast. In this episode, we're unpacking the latest on retatrutide and how it measures up against semaglutide and tirzepatide.  If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  https://pepties.com/partners/ We'll look closely at what the studies tell us so far — from overall weight loss to reductions in visceral fat and how much lean muscle mass is preserved. We'll also talk about where the evidence is solid, where it's still developing, and why cross-trial comparisons should be made with caution. What is retatrutide? So let's start with the basics—what is retatrutide? Retatrutide is a new type of weight-loss medication called a triple agonist. That sounds fancy, but what it really means is that it targets three hormone receptors in the gut and pancreas: GLP-1, GIP, and glucagon. Each of these plays a slightly different role in metabolism and appetite regulation. To break it down: GLP-1, which you might already know from drugs like semaglutide, mainly slows digestion, helps you feel full, and improves insulin sensitivity. GIP, which tirzepatide targets along with GLP-1, also helps regulate blood sugar and may improve how the body stores and burns fat. Retatrutide adds glucagon receptor activation on top of that, which seems to further boost fat burning. So how does this compare to semaglutide and tirzepatide? Semaglutide is a GLP-1-only drug, so it mainly works by reducing appetite and slowing gastric emptying. Tirzepatide is a dual agonist, hitting GLP-1 and GIP, which gives it a slightly stronger effect on blood sugar control and fat metabolism compared to semaglutide. Retatrutide goes one step further by adding glucagon activity, potentially giving more total fat loss. In other words, you can think of it like a spectrum: semaglutide hits one target, tirzepatide hits two, and retatrutide hits three—each additional receptor seems to enhance metabolic effects and fat loss in clinical trials. That's why people are excited about retatrutide, though it's still early, and we're waiting on larger studies to see exactly how it compares head-to-head with the others. And that's going to be key, since right now we don't have direct comparisons to other advanced therapies like semaglutide or tirzepatide in the published Phase 2 data. How does retatrutide compare to semaglutide and tirzepatide? Total body weight loss: Now let's put these three medications side by side and look at what the trials actually tell us about total body weight loss. Starting with retatrutide: in its Phase 2 obesity program, the numbers were unusually large, especially given the relatively short trial window. In the 48-week study, people on the higher doses—8 or 12 milligrams weekly—lost about 22 to 24% of their body weight on average. That's the result that really made headlines. It's worth noting that some trials report slightly different averages depending on the group studied—people with obesity but no diabetes versus people with type 2 diabetes—but across the board, that 48-week signal is consistently very strong. For comparison, let's step back to semaglutide at the 2.4 mg dose, which was tested in the pivotal STEP-1 trial. Over 68 weeks, participants lost about 15% of their body weight on average. That was a landmark finding when it was published in the New England Journal of Medicine—it essentially set the modern benchmark for what a GLP-1 monotherapy could do. Then we have tirzepatide, the dual GIP and GLP-1 agonist. The SURMOUNT-1 trial, which ran for 72 weeks, showed dose-dependent results: about 15% weight loss at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, compared to only around 3% with placebo. Other obesity studies with tirzepatide have backed this up, especially at the higher doses. And in head-to-head comparisons with semaglutide, tirzepatide has consistently come out on top. So if we zoom out: retatrutide's Phase 2 data suggest the greatest average reductions—over 22%—in less than a year. Tirzepatide follows closely behind with around 21% over 72 weeks. And semaglutide shows very meaningful, but smaller, weight loss of around 15% over a similar time frame. The big caveat here is that these aren't perfect apples-to-apples comparisons. The trials differed in their length, the types of patients enrolled—some had type 2 diabetes, some did not—their baseline weights, and even the way results were reported. Plus, retatrutide is still in Phase 2 for obesity, whereas semaglutide and tirzepatide already have large Phase 3 programs and real-world data backing them up. Visceral fat reduction: Next, let's talk about visceral fat reduction—that's the deep fat that surrounds organs like the liver, pancreas, and intestines. It's particularly important because high levels of visceral fat are strongly linked to cardiometabolic disease. Starting with retatrutide, one of the Phase 2 substudies used DEXA scans to measure body composition in detail. At the higher doses—8 and 12 milligrams per week—participants saw visceral fat drop by about 29 to 31% over 48 weeks. That's a very large relative reduction in under a year and one of the reasons people are excited about retatrutide's potential not just for weight loss, but also for improving long-term metabolic health. How does that compare to the other drugs? With semaglutide, we also have DEXA and imaging substudies from the STEP program and follow-up mechanistic work. These consistently show meaningful visceral fat reductions, along with improvements in the ratio of lean to fat mass. The difference is that semaglutide studies typically report VAT changes as “significant and clinically relevant,” but they don't always publish one clear headline number that's directly comparable to retatrutide's ~30%. In other words, semaglutide definitely lowers visceral fat, but depending on the study and population, the exact percentage looks different. For tirzepatide, we also have imaging-based data from the SURMOUNT trials and related body-composition studies. These show that the majority of weight lost is fat mass—including a significant portion of visceral fat. Some analyses report reductions on par with what's seen with GLP-1 therapies, while others suggest tirzepatide may push a bit further. But again, the actual percentages vary depending on whether the study used DEXA, CT, or MRI, and on who was enrolled. The big caveat here is that we don't yet have a head-to-head imaging study comparing all three drugs in the same population with the same methods. Retatrutide's ~30% visceral fat drop is certainly eye-catching, but without that kind of standardized comparison, it's hard to say definitively whether it's truly better than semaglutide or tirzepatide. Lean muscle mass preservation: Now let's shift to lean mass preservation, which is just as important as total weight or fat loss. Across all of the modern obesity drug trials, one thing has been consistent: most of the weight people lose is fat, but some lean tissue is lost too. That's expected whenever you're in a sustained calorie deficit. The question is how much muscle is preserved, and how the proportions break down. With retatrutide, the DEXA substudy showed something reassuring. Even though people lost a lot of total weight and fat, the proportion of lean mass lost compared to total weight loss was similar to what we see with other therapies. In other words, the drug seems to drive large fat reductions without causing disproportionate muscle loss. Interestingly, the absolute amount of lean tissue lost in kilograms was pretty stable across different doses, even though fat loss varied quite a bit. That suggests the extra weight loss with higher doses is really coming from fat, not muscle. Looking at semaglutide, the STEP trials with DEXA scans reported the same general pattern. People lost more fat than lean mass, and when you adjust for the total weight loss, body composition actually improved. In fact, some analyses showed a slight increase in the percentage of body weight that was lean tissue, even though the absolute lean mass in kilograms went down. So again, it's not that muscle isn't affected—it is—but fat loss makes up the majority of the change. For tirzepatide, the SURMOUNT body-composition studies found that about 75% of the weight lost is fat and about 25% is lean mass. That split is very similar to what was seen in the placebo groups, which means the drug isn't shifting the balance unfavorably. It preferentially reduces fat, while lean mass preservation is in the same ballpark as semaglutide and retatrutide. Now, here's the important nuance: lean mass on a DEXA scan isn't just skeletal muscle. It includes water, organ tissue, and other components. So if someone loses 3 or 4 kilograms of “lean mass,” we don't know how much of that is functional muscle versus water or smaller organ size. That's why these numbers can be misleading if you take them at face value. And this is where lifestyle comes in. Resistance training and adequate protein intake are critical alongside medication. Lifting weights or doing bodyweight resistance work helps preserve functional muscle, while getting enough protein—typically somewhere in the range of 0.8 to 1 gram per pound per day depending on age and activity—supports muscle repair and maintenance. Every trial we've seen shows that the best outcomes, in terms of maintaining strength and function, come from pairing these drugs with exercise and nutrition strategies. That way, the unavoidable lean mass changes have far less impact on long-term metabolic health and performance. Limitations, biases, and what's missing (the critical context). No large, peer-reviewed head-to-head trials (yet) comparing retatrutide with semaglutide or tirzepatide for the same endpoints using identical imaging protocols. Most comparisons are cross-trial and therefore imperfect. Retatrutide Phase-2 was often compared to placebo or dulaglutide (in the T2D DEXA substudy) rather than to semaglutide or tirzepatide. A head-to-head (planned/registered) study vs tirzepatide is listed on ClinicalTrials.gov but results are not published yet. Different populations & durations. Some retatrutide data come from cohorts that include people with T2D or NAFLD; semaglutide STEP trials were often in people with obesity (without diabetes) and run longer (68 weeks), while tirzepatide SURMOUNT trials ran to 72 weeks. These differences change the absolute and percent outcomes. Funding and reporting bias. Many of the early retatrutide analyses are industry-funded (Eli Lilly), which is standard for drug development, but it requires us to carefully read methods, endpoints, and completeness of reporting. Independent replication and Phase-3 confirmation matter. Imaging method variation. VAT reported by DXA vs MRI vs CT are not directly interchangeable. Some trials report VAT area, others percent change; that complicates cross-trial percent comparisons.  Thanks for listening to The Peptide Podcast. If today's episode resonated, share it with a friend. Until next time, be well, and as always, have a happy, healthy week.

The latest developments surrounding Ozempic and weight loss continue to generate major interest and headlines, especially with new research and high-profile figures like Oprah Winfrey sharing personal experiences. In the past week, new clinical trial data and ongoing cultural conversations have kept this topic at the forefront.Researchers have revealed that a daily pill version of semaglutide—the active ingredient in Ozempic—can deliver weight loss results comparable to injectables. According to reporting in The New England Journal of Medicine, participants in a 64-week trial who took oral semaglutide lost over 16 percent of their baseline body weight, while those on a placebo lost just 2.7 percent. More than a third of those on the Ozempic pill achieved at least a 20 percent weight reduction. These findings indicate that more convenient alternatives to weekly injections could soon be available for people seeking medical weight management. Cardiovascular risk factors and physical function also improved among those taking the new pill, further supporting its potential for broader approval later in the year.While Ozempic is widely recognized for its effect on appetite—helping users feel full sooner and eat less—the discussion about its effectiveness versus other weight loss methods also remains active. Recent clinical data suggest that surgery still leads to substantially greater average weight loss over time. At New York University, researchers found that patients receiving bariatric surgery lost about 25 percent of their body weight over two years, compared to approximately 5 percent for those sticking with GLP-1 agonists like Ozempic. Factors such as medication adherence and long-term commitment play a massive role in these outcomes. In fact, studies estimate that up to 70 percent of patients may discontinue their weight loss medications within the first year. Experts say this underscores the importance of treating obesity as a chronic and complex disease rather than seeking a one-size-fits-all solution.Oprah Winfrey continues to shape the public conversation about medical weight loss, drawing both criticism and admiration for her openness and candor this week. On her podcast, Oprah confirmed she has used a GLP-1 agonist—though not specifying Ozempic by name—to quiet her mind's “food noise” and help manage her weight. She explained that the drug's effect of mimicking a natural hormone made her realize many people are not waging an internal battle with cravings but simply respond to true hunger and fullness cues. For decades, Oprah says she blamed herself for her struggles, thinking thinness was a matter of willpower or discipline, only to learn that biological predisposition can override even the strongest effort.As she approaches her seventieth birthday, Oprah's primary focus is on maintaining her health and vitality, not just the numbers on the scale. She has emphasized that the medication is one tool in a regimen that includes rigorous exercise, structured meal times, hydration, and dietary principles. In a recent interview, she stressed that there's no shortcut: she hikes daily, counts Weight Watchers points, and drinks a gallon of water each day. Oprah encourages listeners to understand that obesity is a disease based in the brain, and that shame and blame are harmful and misguided. The backlash she faced for admitting she takes medication—some critics say it is the “easy way out”—reflects larger societal debates about medical interventions, with Oprah herself challenging that narrative by sharing her experience of hard work and self-acceptance.Medical experts interviewed in national outlets continue to say that GLP-1 drugs like Ozempic can help people lose between 15 to 20 percent of their body weight when paired with lifestyle changes like healthy eating and physical activity. They caution that success is not just about taking a weekly injection or pill but requires sustained adherence and behavioral support. Side effects like nausea, vomiting, and stomach pain remain a consideration, and patients are advised to consult closely with their health care providers.Meanwhile, innovation in obesity management is accelerating. The upcoming oral formulations of semaglutide and similar molecules could make therapy more accessible and acceptable to a wider population. However, newer approaches, like targeting metabolic pathways beyond appetite control, are on the horizon and may ultimately change how weight is managed over the long term.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Send us a message with this link, we would love to hear from you. Standard message rates may apply.Colon cancer screening saves lives by catching cancer early and even preventing it, yet only 69% of eligible adults are up to date with their screenings. We explore who needs screening, what tests are available, and how to choose the right one for you.• Most adults should start colon cancer screening at age 45, even if healthy• Family history may mean you need to start screening earlier• Stool-based tests like FIT and Cologuard are convenient home options• Colonoscopy remains the gold standard, allowing doctors to remove polyps• One in 23 men and one in 25 women will develop colorectal cancer• The best screening test is the one you'll actually completePlease get screened! Check with your doctor about which test is right for you based on your risk factors and preferences.References1. Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults: A Guidance Statement From the American College of Physicians (Version 2). Qaseem A, Harrod CS, Crandall CJ, et al. Annals of Internal Medicine. 2023;176(8):1092-1100. doi:10.7326/M23-0779.2. AGA Clinical Practice Update on Risk Stratification for Colorectal Cancer Screening and Post-Polypectomy Surveillance: Expert Review. Issaka RB, Chan AT, Gupta S. Gastroenterology. 2023;165(5):1280-1291. doi:10.1053/j.gastro.2023.06.033.3. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. Davidson KW, Barry MJ, Mangione CM, et al. JAMA. 2021;325(19):1965-1977. doi:10.1001/jama.2021.6238.4. Colorectal Cancer Screening and Prevention. Sur DKC, Brown PC. American Family Physician. 2025;112(3):278-283.5. Increasing Incidence of Early-Onset Colorectal Cancer. Sinicrope FA. The New England Journal of Medicine. 2022;386(16):1547-1558. doi:10.1056/NEJMra2200869.6. From Guideline to Practice: New Shared Decision-Making Tools for Colorectal Cancer Screening From the American Cancer Society. Volk RJ, Leal VB, Jacobs LE, et al. CA: A Cancer Journal for Clinicians. 2018;68(4):246-249. doi:10.3322/caac.21459.7. Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Lin JS, Perdue LA, Henrikson NB, Bean SI, Blasi PR. JAMA. 2021;325(19):1978-1998. doi:10.1001/jama.2021.4417.8. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. Bibbins-Domingo K, Grossman DC, Curry SJ, et al. JAMA. 2016;315(23):2564-2575. doi:10.1001/jama.2016.5989.9. How Would You Screen This Patient for Colorectal Cancer? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Burns RB, Mangione CM, Weinberg DS, Kanjee Z. Annals of Internal Medicine. 2022;175(10):1452-1461. doi:10.7326/M22-1961.Support the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

Stress isn't just something to “manage” — it's a signal, a teacher, and often, an invitation to look deeper at our health, our choices, and our lives. In this solo episode, Darin reframes stress not as an enemy, but as a dashboard light pointing toward misalignments in our nervous system, environment, relationships, and purpose. Drawing on science, practical tools, and personal insight, Darin reveals how layered stress silently drains our vitality — and how to transform it into an ally for growth, healing, and deeper contentment. Whether it's hidden trauma, toxic environments, unresolved conflict, or the modern distractions constantly pulling at our attention, Darin lays out a roadmap to stop the leaks and reclaim the energy already within you. This episode is a powerful reminder: stress isn't the end of the story — it's the beginning of awareness, safety, and a super life.     What You'll Learn in This Episode [00:00] Introduction to the Super Life podcast [03:27] Why stress might not be your enemy [04:17] Stress as an ally: the signals it gives us about misalignment [04:32] The dashboard light metaphor: how stress reveals hidden issues [05:28] The illusion of “no choice” and the infinite possibilities always available [06:12] Global stress statistics and why most people underestimate their stress load [07:23] Hidden stress revealed through heart rate variability and physiology [08:23] Layered stress: how sleep, exercise, and poor choices compound each other [09:25] Safety vs. calm — why your nervous system craves safety first [10:15] Trauma and the unconscious mind: how old wounds drive our stress response [11:54] Inner narratives and negative self-talk as hidden stress multipliers [12:22] The role of community and your social field in stress and resilience [13:53] Relationships, honesty, and how your circle shapes your energy [14:55] Why boundaries around media and politics are vital for mental clarity [17:42] Finding micro-purpose when life feels overwhelming [18:52] Environmental layers of stress — light, air, and clutter [19:15] The existential layer: stress from living without service or purpose [20:12] Stress as a risk amplifier — how it undermines healing and health [20:55] The deeper truth of safety, connection, and higher power [23:00] Practical tools: breathing, grounding, nature, and conscious choices [24:01] Trauma reframed: not a problem, but a protector at the time [25:25] Lessons from Peter Levine and wild animals: releasing trauma physically [26:04] Questions to ask trauma: “What are you protecting me from?” [26:56] Stress as a multiplier of aging, disease, and poor outcomes [29:20] Why stress isn't a single cause — it's layered and chronic [30:18] Anti-stress strategies: circadian rhythm, nature, and gratitude [31:49] Energy leaks to avoid: clutter, poor food, scrolling, bad boundaries [32:22] What matters most: service, contribution, and alignment [33:28] Final toolkit: breathwork, movement, nature, sleep, and gratitude [34:38] The deeper invitation: step into sovereignty and live your SuperLife     Thank You to Our Sponsors: Manna Vitality: Go to mannavitality.com/  or use code DARIN20 for 20% off your order. Bite Toothpaste: Go to trybite.com/DARIN20 or use code DARIN20 for 20% off your first order.     Find More from Darin Olien: Instagram: @darinolien Podcast: SuperLife Podcast Website: superlife.com Book: Fatal Conveniences Check out my podcast with Dr. Amy Abbington     Key Takeaway “Stress is not the enemy. It's a dashboard light — a teacher showing you where you're out of alignment. When you reframe stress, you reclaim your energy and create space for healing, safety, and the joy of living a super life.”     Bibliography (selected, peer-reviewed) Sources: Gallup Global Emotions (2024); Gallup U.S. polling (2024); APA Stress in America (2023); Natarajan et al., Lancet Digital Health (2020); Orini et al., UK Biobank (2023); Martinez et al. (2022); Leiden University (2025). Cohen S, Tyrrell DA, Smith AP. Psychological stress and susceptibility to the common cold. N Engl J Med.1991;325(9):606–612. New England Journal of Medicine Cohen S, et al. Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. Proc Natl Acad Sci USA. 2012;109(16):5995–5999. PNAS Kiecolt-Glaser JK, et al. Slowing of wound healing by psychological stress. Lancet. 1995;346(8984):1194–1196. The Lancet Kiecolt-Glaser JK, et al. Hostile marital interactions, proinflammatory cytokine production, and wound healing.Arch Gen Psychiatry. 2005;62(12):1377–1384. JAMA Network Tawakol A, et al. Relation between resting amygdalar activity and cardiovascular events. Lancet.2017;389(10071):834–845. The Lancet Epel ES, et al. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci USA.2004;101(49):17312–17315. PNAS McEwen BS, Stellar E. Stress and the individual: mechanisms leading to disease. Arch Intern Med.1993;153(18):2093–2101. PubMed McEwen BS, Wingfield JC. Allostasis and allostatic load. Ann N Y Acad Sci. 1998;840:33–44. PubMed Felitti VJ, et al. Relationship of childhood abuse and household dysfunction to many leading causes of death in adults (ACE Study). Am J Prev Med. 1998;14(4):245–258. AJP Mon Online Edmondson D, et al. PTSD and cardiovascular disease. Ann Behav Med. 2017;51(3):316–327. PMC Afari N, et al. Psychological trauma and functional somatic syndromes: a systematic review and meta-analysis.Psychosom Med. 2014;76(1):2–11. PMC Goyal M, et al. Meditation programs for psychological stress and well-being: a systematic review and meta-analysis. JAMA Intern Med. 2014;174(3):357–368. PMC Qiu Q, et al. Forest therapy: effects on blood pressure and salivary cortisol—a meta-analysis. Int J Environ Res Public Health. 2022;20(1):458. PMC Laukkanen T, et al. Sauna bathing and reduced fatal CVD and all-cause mortality. JAMA Intern Med.2015;175(4):542–548. JAMA Network Zureigat H, et al. Physical activity lowers CVD risk by reducing stress-related neural activity. J Am Coll Cardiol.2024;83(16):1532–1546. PMC Holt-Lunstad J, Smith TB, Layton JB. Social relationships and mortality risk: a meta-analytic review. PLoS Med.2010;7(7):e1000316. PMC Chen Y-R, Hung K-W. EMDR for PTSD: meta-analysis of RCTs. PLoS One. 2014;9(8):e103676. PLOS Hoppen TH, et al. Network/pairwise meta-analysis of PTSD psychotherapies—TF-CBT highest efficacy overall.Psychol Med. 2023;53(14):6360–6374. PubMed van der Kolk BA, et al. Yoga as an adjunctive treatment for PTSD: RCT. J Clin Psychiatry. 2014;75(6):e559–e565. PubMed Kelly U, et al. Trauma-center trauma-sensitive yoga vs CPT in women veterans: RCT. JAMA Netw Open.2023;6(11):e2342214. JAMA Network Bentley TGK, et al. Breathing practices for stress and anxiety reduction: components that matter. Behav Sci (Basel). 2023;13(9):756. 

Comment se déroule l'ouverture d'un centre de dialyse péritonéale ? Quels sont les acteurs nécessaires pour démarrer cette activité ? Comment les équipes d'infirmières diplômées d'État sont-elles formées à la dialyse péritonéale ? Comment se passe le recrutement patient ? Quels conseils donner à un professionnel de santé qui souhaiterait démarrer une activité de dialyse péritonéale ? Comment présenter les différents moyens de suppléance rénale aux patients ? Le Dr Guillaume Seret, néphrologue au Centre Dialyse Echo Le Mans, répond à ces questions.   Invité : Dr Guillaume Seret, néphrologue au Centre Dialyse Echo Le Mans. Le Dr Seret déclare ne pas avoir de lien d'intérêt en rapport avec le sujet traité   L'équipe :
 Animation :  Pyramidale Communication Production : Pyramidale Communication   Crédits : Pyramidale Communication, Sonacom   Ce podcast est uniquement destiné à des fins d'information. Si vous souhaitez contacter Baxter pour de plus amples informations ou pour signaler un événement indésirable, veuillez consulter notre site web à l'adresse suivante : https://www.baxter.fr/fr/contact-us   Référence : Teitelbaum I. Peritoneal Dialysis, The New England Journal of Medicine, 2021 Nov 4;385(19):1786-1795. doi: 10.1056/NEJMra2100152.

Welcome to PsychEd, the psychiatry podcast for medical learners, by medical learners. This short episode covers the basics of electroconvulsive therapy.Hosts: Ravi Bhindi (CC3), Dr. Angad Singh (PGY2)Audio Editing: Dr. Angad Singh (PGY2)Show Notes: Dr. Angad Singh (PGY2)Time Stamps:(0:36) - What is ECT?(2:18) - Indications and efficacy(4:35) - Treatment course(4:32) - Combination treatment(6:33) - Medications to discontinue(8:16) - Contraindications(9:40) - Side effects(11:52) - Procedure(16:03) - SummaryResources:https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/electroconvulsive-therapyhttps://sunnybrook.ca/content/?page=psychiatry-electroconvulsive-therapy-ect-faqReferences:Andrade, C., Arumugham, S. S., & Thirthalli, J. (2016). Adverse Effects of Electroconvulsive Therapy. The Psychiatric clinics of North America, 39(3), 513–530.Brakemeier, E. L., Merkl, A., Wilbertz, G., Quante, A., Regen, F., Bührsch, N., van Hall, F., Kischkel, E., Danker-Hopfe, H., Anghelescu, I., Heuser, I., Kathmann, N., & Bajbouj, M. (2014). Cognitive-behavioral therapy as continuation treatment to sustain response after electroconvulsive therapy in depression: a randomized controlled trial. Biological psychiatry, 76(3), 194–202.Espinoza, R. T., & Kellner, C. H. (2022). Electroconvulsive therapy. New England Journal of Medicine, 386(7), 667-672.Gill, S., Hussain, S., Purushothaman, S., Sarma, S., Weiss, A., Chamoli, S., ... & Loo, C. K. (2023). Prescribing electroconvulsive therapy for depression: Not as simple as it used to be. Australian & New Zealand Journal of Psychiatry, 57(9), 1202-1207.Janjua, A. U., Dhingra, A. L., Greenberg, R., & McDonald, W. M. (2020). The efficacy and safety of concomitant psychotropic medication and electroconvulsive therapy (ECT). CNS Drugs, 34(5), 509-520.Jelovac, A., Kolshus, E., & McLoughlin, D. M. (2013). Relapse following successful electroconvulsive therapy for major depression: a meta-analysis. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 38(12), 2467–2474.Kolshus, E., Jelovac, A., & McLoughlin, D. M. (2017). Bitemporal v. high-dose right unilateral electroconvulsive therapy for depression: a systematic review and meta-analysis of randomized controlled trials. Psychological Medicine, 47(3), 518-530.Lam, R. W., Kennedy, S. H., Adams, C., Bahji, A., Beaulieu, S., Bhat, V., ... & Milev, R. V. (2024). Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023: Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes. The Canadian Journal of Psychiatry, 69(9), 641-687.Luchini, F., Medda, P., Mariani, M. G., Mauri, M., Toni, C., & Perugi, G. (2015). Electroconvulsive therapy in catatonic patients: Efficacy and predictors of response. World journal of psychiatry, 5(2), 182–192.Tess, A. V., & Smetana, G. W. (2009). Medical evaluation of patients undergoing electroconvulsive therapy. New England Journal of Medicine, 360(14), 1437-1444.Zolezzi M. (2016). Medication management during electroconvulsant therapy. Neuropsychiatric disease and treatment, 12, 931–939.For more PsychEd, follow us on Instagram (@psyched.podcast),  Facebook (PsychEd Podcast), X (@psychedpodcast), and Bluesky (@psychedpodcast.bsky.social‬). You can email us at psychedpodcast@gmail.com and visit our website at psychedpodcast.org.

Send us a message with this link, we would love to hear from you. Standard message rates may apply.The DASH diet offers a powerful, evidence-based approach to lowering blood pressure through nutritional changes rather than medication.• Stands for Dietary Approaches to Stop Hypertension• Focuses on fruits, vegetables, whole grains, lean proteins, and low-fat dairy• Limits sodium, saturated fat, added sugars, and processed meats• Can lower systolic blood pressure by 5-6 points and diastolic by 3 points• Recommends 4-5 servings each of fruits and vegetables daily• Suggests 6-8 servings of whole grains per day• Advises limiting sodium to 1,500mg daily for those with hypertension• Provides numerous meal ideas including oatmeal with berries, turkey sandwiches, and grilled salmon• Encourages using herbs and spices instead of salt for flavoring• Benefits extend beyond blood pressure to include improved cholesterol and weight managementFor more information about hypertension management, check out our previous episodes: episode 4 (explaining hypertension), episode 5 (lifestyle changes), episode 14 (common medications), and episode 33 (measuring blood pressure at home).References1. Diets. Yannakoulia M, Scarmeas N. The New England Journal of Medicine. 2024;390(22):2098-2106. doi:10.1056/NEJMra2211889.2. Treatment of Hypertension: A Review. Carey RM, Moran AE, Whelton PK. JAMA. 2022;328(18):1849-1861. doi:10.1001/jama.2022.19590.3. DASH Dietary Pattern and Cardiometabolic Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses. Chiavaroli L, Viguiliouk E, Nishi SK, et al. Nutrients. 2019;11(2):E338. doi:10.3390/nu11020338.4. Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society* Clinical Practice Guideline. Rosenzweig JL, Bakris GL, Berglund LF, et al. The Journal of Clinical Endocrinology and Metabolism. 2019;104(9):3939-3985. doi:10.1210/jc.2019-01338.5. Recommended Dietary Pattern to Achieve Adherence to the American Heart Association/American College of Cardiology (AHA/ACC) Guidelines: A Scientific Statement From the American Heart Association. Van Horn L, Carson JA, Appel LJ, et al. Circulation. 2016;134(22):e505-e529. doi:10.1161/CIR.0000000000000462.6. Dietary Approaches to Stop Hypertension (DASH) for the Primary and Secondary Prevention of Cardiovascular Diseases. Bensaaud A, Seery S, Gibson I, et al. The Cochrane Database of Systematic Reviews. 2025;5:CD013729. doi:10.1002/14651858.CD013729.pub2.7. Popular Dietary Patterns: Alignment With American Heart Association 2021 Dietary Guidance: A Scientific Statement From the American Heart Association. Gardner CD, Vadiveloo MK, Petersen KS, et al. Circulation. 2023;147(22):1715-1730. doi:10.1161/CIR.0000000000001146.8. Dietary Approaches to Prevent and Treat Hypertension: A Scientific Statement From the American Heart Association. Appel LJ, Brands MW, Daniels SR, et al. Hypertension (Dallas, Tex. : 1979). 2006;47(2):296-308. doi:10.1161/01.HYP.0000202568.01167.B6.9. Dietary Approaches to Stop Hypertension (DASH): Potential Mechanisms of Action Against Risk Factors of the Metabolic Syndrome. Akhlaghi M. Nutrition Research Reviews. 2020;33(1):1-18. doi:10.1017/S0954422419000155.10. The Effects of the Dietary Approaches to Stop Hypertension (DASH) Diet on Metabolic Risk Factors in Patients With Chronic Disease: Support the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

Back pain is one of the most common health problems in the world — but also one of the most mysterious. Scans don't always match symptoms, treatments don't always provide relief, and many people feel stuck with ongoing discomfort.In this episode, I explore chronic, non-specific low back pain through a biopsychosocial lens. Basically, we're looking beyond just the spine to understand how biology, psychology, and environment all shape the way pain is experienced.You'll hear about:What makes non-specific low back pain so puzzlingHow pain perception actually works (pain ≠ tissue damage)Why the biopsychosocial model is key to understanding painThe role of self-regulation in shaping pain responsesWhat research says about meditation for back painHow to reframe back pain when you feel like you're hitting a wallJournal prompts to reflect on your own experienceBy the end, you'll have a new way to think about back pain, one that expands the options for healing beyond the body alone.Engel, G. L. (1977). The need for a new medical model: a challenge for biomedicine. Science, 196(4286), 129–136. (Origin of the biopsychosocial model)Study on self-regulation and pain: Wager, T. D., et al. (2013). An fMRI-based neurologic signature of physical pain. New England Journal of Medicine, 368(15), 1388–1397. (and related follow-up studies on cognitive self-regulation impacting autonomic markers — you summarised one in your notes)Systematic review on meditation and back pain: Cramer, H., et al. (2022). Meditation for adults with non-specific low back pain: a systematic review and meta-analysis. (Included 8 RCTs, ~1,234 participants, moderate-certainty evidence of small benefits for disability and long-term pain

In this episode of the RWS Clinician's Corner, Margaret Floyd Barry takes us behind the scenes into the dynamic world of research and curriculum development in the functional health space. Margaret sits down with two of Restorative Wellness Solutions' powerhouse instructors, Ellen Lovelace and Paige Reagan, for a candid conversation about the challenges, surprises, and daily realities of translating emerging science into practical, safe, and effective tools for clinicians.   In this interview, we discuss:     -Specific ways that Ellen & Paige demonstrate curriculum leadership and research support for RWS   -How to respond to new studies or challenges to existing curriculum    -How to decide which sources to trust   -How to evaluate clinical research (red & green flags)   -Addressing research limitations and gaps    -Using research tools and AI in gathering evidence   The Clinician's Corner is brought to you by Restorative Wellness Solutions.  Follow us: https://www.instagram.com/restorativewellnesssolutions/    Connect with Ellen:  Website: www.abalancedtable.net Facebook: www.facebook.com/abalancedtable Instagram: www.instagram.com/abalancedtable   Connect with Paige: Website: www.naturallynourishedwellness.com Instagram: www.instagram.com/paigereaganntp   Timestamps: 00:00 From Russian Studies to Health Advocacy 07:56 Curriculum Accuracy and Depth Focus 12:57 Using AI for Study Validation 19:20 Evaluating Research Article Credibility 25:24 Animal Study Relevance and Limitations 28:03 "Pediatric Research Gaps in Drug Trials" 33:55 "Teaching Deepens Understanding" 41:17 Questioning AI for Balanced Answers 44:47 Effective Research Strategies and AI Limitations 52:04 Verify Before Believing Headlines 55:52 "Unpaywall: Access Free Academic Papers" 01:00:33 "The Clinician's Corner Podcast" Speaker bios: Ellen Lovelace, Lead Instructor & Curriculum Development Master RHP, MPH, FNTP, Board Certified in Holistic Nutrition® Ellen (she/her) has been actively working to educate and improve the public's health for almost 20 years. Ellen received her Masters in Public Health from The George Washington University, and went on to run everything from tuberculosis prevention programs in Russia to dental health education programs along the Texas/Mexico border. She was also the founding Executive Director of the women's health program at Stanford University. When Ellen became drawn to a more holistic model, she received her certifications as a Nutritional Therapy Consultant and a Master Restorative Health Practitioner. She is the owner of A Balanced Table Nutritional Therapy in San Jose, CA, her private functional nutrition practice. Ellen focuses on cutting through the confusion and nutrition “noise,” digging to the roots of clients' dysfunction, and figuring out the best way for them to eat, drink, and thrive. She uses the IRH functional analysis tools daily, and is excited to share her passion for these methods. Ellen believes that only by focusing on root causes, combined with whole foods nutrition, can true wellness be achieved. Ellen is also a passionate animal lover who volunteers at a wildlife rescue facility, and can often be found smelling of skunk while covered in Mastiff drool.    Paige Reagan, Instructor and Research Master RHP, FNTP Paige has spent most of her career working in Research and Development in the areas of clinical research, regulatory affairs, and medical writing. She has a wide range of experience in the therapeutic areas of cardiovascular health, pulmonary arterial hypertension, diabetes, bone health, osteoarthritis/rheumatoid arthritis, and urology, among others. Her work has contributed to numerous regulatory approvals as well as publications in major medical journals such as the New England Journal of Medicine, Lancet, Circulation, and American Heart Journal. Paige has since earned certifications as a Functional Nutritional Therapy Practitioner and Master Restorative Health Practitioner. She is owner of Naturally Nourished Wellness, a small practice specializing in gut health and the downstream effects of poor digestion. She strives to find balance between the holistic and mainstream approaches and aims to provide her clients with the best of both worlds, using her critical thinking skills from years in research combined with objective laboratory testing and her passion for the restorative power of whole foods and simple lifestyles. She spends her free time exploring the outdoors with her family, swinging kettlebells, and creating baked goods with healthier ingredients.   Keywords: functional nutrition, public health, research process, curriculum development, clinical research, regulatory affairs, medical writing, gastrointestinal healing, lab testing, food sensitivities, evidence-based practice, study design, randomized controlled trials, observational studies, animal studies, peer review, PubMed, Google Scholar, AI tools in research, ChatGPT, consensus, study citations, clinical anecdote, sample size, funding bias, meta-analysis, systematic reviews, biostatistics, clinical protocols, dietary supplements   Disclaimer: The views expressed in the RWS Clinician's Corner series are those of the individual speakers and interviewees, and do not necessarily reflect the views of Restorative Wellness Solutions, LLC. Restorative Wellness Solutions, LLC does not specifically endorse or approve of any of the information or opinions expressed in the RWS Clinician's Corner series. The information and opinions expressed in the RWS Clinician's Corner series are for educational purposes only and should not be construed as medical advice. If you have any medical concerns, please consult with a qualified healthcare professional. Restorative Wellness Solutions, LLC is not liable for any damages or injuries that may result from the use of the information or opinions expressed in the RWS Clinician's Corner series. By viewing or listening to this information, you agree to hold Restorative Wellness Solutions, LLC harmless from any and all claims, demands, and causes of action arising out of or in connection with your participation. Thank you for your understanding.  

Welcome to the Plant-Based Canada Podcast! In today's episode, we're joined by Dr. Joan Sabaté, a renowned physician and nutrition researcher, best known for his work on environmental and sustainable nutrition, and the health benefits of nuts and plant-based diets.Dr. Joan Sabaté MD, PhD is a Professor of Nutrition and Epidemiology. He directs the Environmental Nutrition research program at Loma Linda University School of Public Health and he is also a board-certified physician in Internal Medicine. He was the principal investigator of a nutrition intervention trial that directly linked the consumption of walnuts to significant reductions in serum cholesterol, published in the New England Journal of Medicine in 1993. He is a co-investigator of the Adventist Health Studies, the largest cohort of individuals following a vegetarian diet relating dietary intake with health outcomes. For the past 25 years, he has been the principal investigator of many human nutrition intervention trials investigating the health effects of nuts, avocados, and other plant foods. Dr. Sabaté has authored more than 200 high-impact research articles (with an h-index of 82 and >40,000 citations). Additionally, he was a member of the US 2020 Dietary Guidelines Advisory Committee.Resources:Adventist Health Study 2 Studies: https://pubmed.ncbi.nlm.nih.gov/23836264/; https://pubmed.ncbi.nlm.nih.gov/30487555/Whole-food, plant-based lifestyle intervention trial: https://pubmed.ncbi.nlm.nih.gov/39305340/Review of Plant-Based Milks: https://pubmed.ncbi.nlm.nih.gov/36083996/ 2020 Dietary Guidelines for Americans: https://www.dietaryguidelines.gov/resources/2020-2025-dietary-guidelines-online-materialsNuts & Health: https://pubmed.ncbi.nlm.nih.gov/8357360/https://pubmed.ncbi.nlm.nih.gov/8269904/ https://pubmed.ncbi.nlm.nih.gov/15559025/https://pubmed.ncbi.nlm.nih.gov/10479222/Dr. Joan Sabaté's Socials:Faculty profileInternational Congress of Vegetarian NutritionEnvironmental NutritionLLU Nutrition CenterPlant-Based Canada's Socials:InstagramFacebookWebsiteBonus PromotionCheck out University of Guelph's online Plant-Based Nutrition Certificate. Each 4-week course will guide you through plant-based topics including nutritional benefits, disease prevention, and environmental impacts. Use our exclusive discount code PBC2025 to save 10% on all Plant-Based Nutrition Certificate courses. uoguel.ph/pbn.Thank you for tuning in! Make sure to subscribe to the Plant-Based Canada Podcast so you get notified when new episodes are published. Support the show

Send us a message with this link, we would love to hear from you. Standard message rates may apply.The flu vaccine is our best defense against influenza, a contagious respiratory virus that causes millions of illnesses and thousands of deaths in the US each year. Despite being only 40-60% effective, the vaccine significantly reduces hospitalizations, outpatient visits, and deaths while protecting vulnerable populations who cannot be vaccinated.• Influenza causes 9-41 million illnesses, 140,000-960,000 hospitalizations, and 12,000-80,000 deaths annually in the US• Everyone aged six months and older should receive the flu vaccine yearly• The vaccine must be updated annually because the flu virus changes each year• Getting vaccinated helps protect vulnerable populations like infants and immunocompromised individuals• Common misconception that the vaccine causes flu is false – it cannot give you the flu• Only 40-46% of Americans get the flu vaccine annually despite its proven benefits• The best time to get vaccinated is before flu season begins, but getting it later still helps• Flu vaccination reduces strain on hospitals during peak seasonsGo get your flu shot today! It's the best way to protect yourself, your loved ones, and your neighbors ReferencesPrevention and Control of Seasonal Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 Influenza Season. Grohskopf LA, Blanton LH, Ferdinands JM, et al. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2022;71(1):1-28. doi:10.15585/mmwr.rr7101a1. Copyright License: CC0.Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2019;68(6):e1-e47. doi:10.1093/cid/ciy866.Influenza Vaccination. Treanor JJ. The New England Journal of Medicine. 2016;375(13):1261-8. doi:10.1056/NEJMcp1512870.Effects of Influenza Vaccination in the United States During the 2017-2018 Influenza Season. Rolfes MA, Flannery B, Chung JR, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2019;69(11):1845-1853. doi:10.1093/cid/ciz075.Vaccines for Preventing Influenza in Healthy Adults. Demicheli V, Jefferson T, Ferroni E, Rivetti A, Di Pietrantonj C. The Cochrane Database of Systematic Reviews. 2018;2:CD001269. doi:10.1002/14651858.CD001269.pub6.Recommendations for Prevention and Control of Influenza in Children, 2022-2023. Pediatrics. 2022;150(4):e2022059275. doi:10.1542/peds.2022-059275.Influenza. Uyeki TM. Annals of Internal Medicine. 2021;174(11):ITC161-ITC176. doi:10.7326/AITC202111160.Support the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

Send us a textIn this episode of Causes or Cures, Dr. Eeks chats with Dr. Irene Papanicolas, Professor of Health Services, Policy and Practice at Brown University, about her recent New England Journal of Medicine paper examining the links between wealth and mortality across the United States and Europe.There's a lot of focus on longevity today, from biohackers chasing longer lives to new medical innovations. But how much does the money in your bank account matter when it comes to lifespan? And why do those relationships between wealth and health look different across countries?The study analyzed data from over 73,000 adults, exploring how wealth impacts lifespan within and across countries, including comparisons between the wealthiest and poorest quartiles, the concept of a “survivor effect,” and why even wealthy Americans may be dying earlier than poorer Europeans.We discuss:How “wealth” was defined in the study.The differences in life expectancy between the U.S. and Europe.What factors might explain why U.S. outcomes lag (diet, food environment, culture, lack of universal healthcare).Which European countries stood out for protecting longevity.Policy implications, and what interventions could have the biggest impact if implemented tomorrow. Read the full paper here: NEJM: Wealth, Mortality, and the U.S.–Europe GapIf you're curious about the intersections of wealth, health, and longevity, and want to understand what money can (and can't) buy when it comes to living longer, this episode is for you. Dr. Irene Papanicolas is a Professor of Health Services Policy and Practice at Brown University. A health economist and researcher, her work focuses on assessing how health systems perform and using international comparisons to inform policy. She leads the International Collaborative on Costs, Outcomes and Needs in Care (ICCONIC), a 16-country partnership studying care patterns and outcomes for high-need, high-cost patients. Dr. Papanicolas has published widely on health system performance and cross-country comparisons. You can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Or Facebook here.Or X.On Youtube.Or TikTok.SUBSCRIBE to her monthly newsletter here! (Now featuring interviews with top experts on health you care about!)Support the show

There's a lot of talk about the Mediterranean Diet, and when you think about this way of eating, olive oil usually comes to mind. Is this just a fad, or are there some facts to back up the claims of heart health, longevity and anti-inflammatory factors when people consume olive oil?Rob and Sandra review some evidence and look at factors that may influence why olive oil has this distinctive reputation. Predimed study from the  New England Journal of Medicine:"Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts" https://pubmed.ncbi.nlm.nih.gov/29897866/Episodes mentioned include:Nutrition Nuggets 81 - How to Use Olive Oil https://youtu.be/jpzzuzGJ6doEp 172. Do Dietary Fats Affect Inflammation?https://youtu.be/OOSLRwNBPG8Ep 23. Fats, Grease and Oils - Quality over Quantity: Lubricate the Body and Skin From Within https://youtu.be/otQdbY-s_voNutrition Nuggets 21 - Butter vs Margarinehttps://youtu.be/NIT8C3gw7NAEnjoying the show? Consider leaving a 5 star review, and/or sharing this episode with your friends and family :)Sign up for our newsletter on our website for weekly updates and other fun info. You can also visit our social media pages. We're on⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, and⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.Your support helps fuel the stoke and keeps the show going strong every week. Thanks!Website: www.mywifethedietitian.comEmail: mywifetherd@gmail.com

Grazia Aleppo, MD, Kasey J. Coyne, MD, and Jelena Kravarusic, MD, PhD, from the Northwestern Medicine Division of Endocrinology, join the Better Edge podcast. The trio discusses a recent clinical trial they led, published in The New England Journal of Medicine. This trial aimed to evaluate the efficacy and safety of using an automated insulin delivery system for treating patients with Type 2 diabetes, a method already well established for those with Type 1 diabetes.

Dr Azra Raza is a Professor of Medicine, Clinical Director of the Evans Foundation MDS Center, and Executive Director of The First Cell Coalition for Cancer Survivors at Columbia University in New York. She is the best-selling author of "The First Cell: And the human costs of pursuing cancer to the last". She started her research in Myelodysplastic Syndromes (MDS) in 1982 and moved to Rush University, Chicago, Illinois in 1992, where she was the Charles Arthur Weaver Professor in Oncology and Director, Division of Myeloid Diseases. The MDS Program, along with a Tissue Repository containing more than 50,000 samples from MDS and acute leukemia patients was successfully relocated to the University of Massachusetts in 2004 and to Columbia University in 2010. Before moving to New York, Dr Raza was the Chief of Hematology Oncology and the Gladys Smith Martin Professor of Oncology at the University of Massachusetts in Worcester. She has published the results of her laboratory research and clinical trials in prestigious, peer-reviewed journals such as The New England Journal of Medicine, Nature, Blood, Cancer, Cancer Research, the British Journal of Hematology, Leukemia, and Leukemia Research. Dr Raza serves on numerous national and international panels as a reviewer, consultant, and advisor and is the recipient of a number of awards.TIMESTAMPS:(0:00) - Introduction (0:50) - The First Cell: and the human costs of pursuing cancer to the last(4:10) - Defining Cancer(7:50) - A Cancer Paradigm Shift: Finding the First Cell(11:16) - "The Cure for Cancer"(19:05) - Azra's Journey, Development & Reception(24:40) - Hope, Honesty & Harm in a Clinical Setting(33:00) - Current Medical Politics vs Revolutionary Detections/Treatments(39:00) - Increasing Lifespan & Healthspan(43:01) - "Michael Levin Should Win The Nobel Prize!"(51:00) - A Good Life & a Good Death(56:00) - How Words distort our relationship with Disease(1:00:00) - How Disease & Death Shape Our Lives(1:05:40) - The First Cell Book(1:09:15) - A Better Healthcare System(1:12:27) - Conclusion EPISODE LINKS:- Azra's Website: https://azraraza.com- Azra's Books: https://azraraza.com/books- Azra's X: https://x.com/AzraRazaMD- Azra's YouTube: http://www.youtube.com/@AzraRazaMDCONNECT:- Website: https://tevinnaidu.com - Podcast: https://creators.spotify.com/pod/show/mindbodysolution- YouTube: https://youtube.com/mindbodysolution- Twitter: https://twitter.com/drtevinnaidu- Facebook: https://facebook.com/drtevinnaidu - Instagram: https://instagram.com/drtevinnaidu- LinkedIn: https://linkedin.com/in/drtevinnaidu=============================Disclaimer: The information provided on this channel is for educational purposes only. The content is shared in the spirit of open discourse and does not constitute, nor does it substitute, professional or medical advice. We do not accept any liability for any loss or damage incurred from you acting or not acting as a result of listening/watching any of our contents. You acknowledge that you use the information provided at your own risk. Listeners/viewers are advised to conduct their own research and consult with their own experts in the respective fields.

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:1. Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The US POINTER Randomized Clinical Trial JAMA 2025.  Discussion by:Guest:Philip Lieberman, MDResident- Family Medicine Residency ProgramJefferson Health - Abington2. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial.  New England Journal of Medicine 2025 Discussion by:Guest:Donna Ryan, MDProfessor Emerita at Pennington Biomedical Baton Rouge, LA, USA3. Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: a randomized, controlled clinical trial. Alzheimer's Research & Therapy.  Discussion by:Guest:Kathryn Donnelly, DOResident– Family Medicine Residency ProgramJefferson Health – AbingtonMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Send us a textCar accidents are the leading cause of death for kids, teens, and young adults — but so many are preventable. In this episode, I sit down with my dad, pediatrician Dr. Andrew Matthew (and the safest driver I know!), to talk about what parents and teens can do to stay safe on the road.Using information from this recent article:Motor Vehicle Crash Prevention, New England Journal of Medicine, Vol 393, Issue 5 (July 31 2025)We discuss:Why car accidents are the #1 cause of death for ages 5–29How texting while driving raises your crash risk 23-foldPractical tips for teaching teens to drive safelyThe truth about speeding, tailgating, and road rageWhen technology helps — and when it hurtsSmart ways to talk to kids about car safetyIf you've got a new driver at home, carpool often, or just want to be more mindful behind the wheel, this episode is full of practical, potentially life-saving tips.Your Child is Normal is the trusted podcast for parents, pediatricians, and child health experts who want smart, nuanced conversations about raising healthy, resilient kids. Hosted by Dr. Jessica Hochman — a board-certified practicing pediatrician — the show combines evidence-based medicine, expert interviews, and real-world parenting advice to help listeners navigate everything from sleep struggles to mental health, nutrition, screen time, and more. Follow Dr Jessica Hochman:Instagram: @AskDrJessica and Tiktok @askdrjessicaYouTube channel: Ask Dr Jessica If you are interested in placing an ad on Your Child Is Normal click here or fill out our interest form.-For a plant-based, USDA Organic certified vitamin supplement, check out : Llama Naturals Vitamin and use discount code: DRJESSICA20-To test your child's microbiome and get recommendations, check out: Tiny Health using code: DRJESSICA The information presented in Ask Dr Jessica is for general educational purposes only. She does not diagno...

The Food and Drug Administration or FDA regulates roughly 78% of the US food supply. This includes packaged products, food additives, infant formula, ultra-processed foods, and lots more. However, an analysis by the Environmental Working Group found that 99% of new food ingredients enter our food supply through a legal loophole that skirts FDA oversight and seems, to me at least, to be incredibly risky. Today we're speaking with two authors of a recent legal and policy analysis published in the Journal Health Affairs. They explain what this loophole is and its risks and suggest a new user fee program to both strengthen the FDA's ability to regulate food ingredients and address growing concerns about food safety. Our guests are Jennifer Pomeranz Associate Professor of Public Health Policy and Management at New York University School of Global Public Health and Emily Broad, director of Harvard Law School Center for Health Law and Policy Innovation. Interview Summary So Jennifer, let's start with you, help our listeners understand the current situation with food ingredient oversight. And what is this legal loophole that allows food companies to add new ingredients without safety reviews. Sure. So, Congress passed the Food Additives Amendment in 1958, and the idea was to divide food additives and generally recognized as safe ingredients into two different categories. That's where the GRAS term comes from generally recognized as safe? ‘Generally Recognized As Safe' is GRAS. But it circularly defines food additives as something that's not GRAS. So, there's not actually a definition of these two different types of substances. But the idea was that the food industry would be required to submit a pre-market, that means before it puts the ingredient into the marketplace, a pre-market petition to the FDA to review the safety. And then the FDA promulgates a regulation for safe use of a food additive. GRAS ingredients on the other hand, initially thought of as salt, pepper, vinegar, are things like that would just be allowed to enter the food supply without that pre-market petition. The problem is the food industry is the entity that decides which category to place each ingredient. There's no FDA guidance on which category they're supposed to ascribe to these ingredients. What has happened is that the food industry has now entered into the food supply an enormous amount of ingredients under what we call the GRAS loophole, which is allowing it to just bring it to the market without any FDA oversight or even knowledge of the ingredient. So, in essence, what we're having now is that the food industry polices itself on whether to submit this pre-market petition for a food additive or just include it in its products without any FDA knowledge. When you said ‘enormous number of such things,' are we talking dozens, hundreds, thousands? Nobody knows, but the environmental working group did find that 99% of new ingredients are added through this loophole. And that's the concerning part. Well, you can look at some ultra-processed foods and they can have 30 or 40 ingredients on them. That's just one food. You can imagine that at across the food supply, how many things there are. And there are these chemicals that nobody can pronounce. You don't know what's going on, what they are, what they're all about. So, what you're saying is that the food industry decides to put these things in foods. There's some processing reason for putting them in. It's important that the public be protected against harmful ingredients. But the food industry decides what's okay to put in and what's not. Are they required to do any testing? Are there criteria for that kind of testing? Is there any sense that letting the industry police itself amounts to anything that protects the public good? Well, the criteria are supposed to be the same for GRAS or food additives. They're supposed to be meeting certain scientific criteria. But the problem with this is that for GRAS ingredients, they don't have to use published data and they can hold that scientific data to themselves. And you mentioned food labels, the ingredient list, right? That doesn't necessarily capture these ingredients. They use generic terms, corn oil, color additive, food additive whatever. And so, the actual ingredient itself is not necessarily listed on the ingredient list. There is no way to identify them and it's unknown whether they're actually doing the studies. They can engage in these, what are called GRAS panels, which are supposed to be experts that evaluate the science. But the problem is other studies have found that 100% of the people on these GRAS panels have financial conflicts of interest. Okay, so let me see if I have this right. I'm a food company. I develop a new additive to provide color or flavor or fragrance, or it's an emulsifier or something like that. I develop a chemical concoction that hasn't really been tested for human safety. I declare it safe. And the criteria I use for declaring it set safe is putting together a panel of people that I pay, who then in a hundred percent of cases say things are. That's how it works? I can't say that in a hundred percent of cases they say it's safe, but a hundred percent of the people have financial conflicts of interest. That's one of the major concerns there. Well, one can't imagine they would continue to be paid... Exactly. This sounds like a pretty shaky system to be sure. Emily: I wanted to add a couple other really quick things on the last discussion. You were saying, Kelly, like they're using a panel of experts, which indeed are paid by them. That would be best case in some cases. They're just having their own staff say, we think this is generally recognized as safe. And I think there's some examples we can give where there isn't even evidence that they went to even any outside people, even within industry. I think that the takeaway from all of that is that there's really the ability for companies to call all the shots. Make all the rules. Not tell FDA what they're doing. And then as we talked about, not even have anything on the label because it's not a required ingredient if it's, used as part of a processing agent that's not a substance on there. So I was feeling pretty bad when Jennifer is talking about these panels and the heavy conflict... Even worse. Of interest, now I feel worse because that's the best case. Totally. And one other thing too is just you kind of warmed this up by talking about this loophole. When we put an earlier article out that we wrote that was about just this generally recognized as safe, the feedback we got from FDA was this isn't a loophole. Why are you calling this a loophole? And it's pretty clear that it's a loophole, you know? It's big enough to drive thousands of ingredients through. Yes, totally. Emily, you've written about things like partially hydrogenated vegetable oils, trans fats, and red dye number three in particular. Both of which FDA has now prohibited in food. Can you walk us through those cases? You asked about partially hydrogenated oils or trans-fat, and then red dye three, which are two examples that we talk about a little bit in our piece. Actually, one of those, the partially hydrogenated oils was allowed in food through the generally recognized as safe definition. And the other was not. But they are both really good examples of another real issue that FDA has, which is that not only are they not doing a good job of policing substances going into food on the front end, but they do an even worse job of getting things out of food on the backend, post-market once they know that those substances are really raising red flags. And you raised two of the prime examples we've been talking about. With partially hydrogenated oils these are now banned in foods, but it took an extremely long time. Like the first evidence of harm was in the mid-nineties. By 2005, the Institute of Medicine, which is now the National Academies, said that intake of trans fat, of partially hydrogenated oils, should be as low as possible. And there was data from right around that time that found that 72,000 to 228,000 heart attacks in the US each year were caused by these partially hydrogenated oils. And on FDA's end, they started in early 2000s to require labeling. But it wasn't until 2015 that they passed a final rule saying that these substances were not generally recognized as safe. And then they kept delaying implementation until 2023. It was basically more than 20 years from when there was really clear evidence of harm including from respected national agencies to when FDA actually fully removed them from food. And red dye number three is another good example where there were studies from the 1980s that raised concerns about this red dye. And it was banned from cosmetics in 1990. But they still allowed it to be added to food. And didn't ban it from food until early this year. So early 2025. In large part because one of the other things happening is states are now taking action on some of these substances where they feel like we really need to protect consumers in our states. And FDA has been doing a really poor job. California banned red dye about 18 months before that and really spurred FDA to action. So that 20-year delay with between 72,000 and 228,000 heart attack deaths attributable to the trans fats is the cost of delay and inaction and I don't know, conflicts of interest, and all kinds of other stuff that happened in FDA. So we're not talking about something trivial by any means. These are life and death things are occurring. Yes. Give us another example, if you would, about something that entered the food supply and caused harm but made it through that GRAS loophole. The example that I've talked about both in some of the work we've done together and also in a perspective piece in the New England Journal of Medicine that really focused on why this is an issue. There was this substance added to food called tara flour. It came on the scene in 2022. It was in food prepared by Daily Harvest as like a protein alternative. And they were using it from a manufacturer in South America who said we have deemed this generally recognized as safe. Everything about that is completely legal. They deemed it generally recognized as safe. A company put it into food, and they sold that. Up until that point, that's all legal. What happened was very quickly people started getting really sick from this. And so there were, I think, about 400 people across 39 states got sick. Nearly 200 people ended up in the hospital, some of them with liver failure because of this toxicity of tara flour. And so FDA followed the thread they did help work with the company to do a voluntary recall, but it then took them two years, until May, 2024, to declare tara flour not generally recognized as safe. So I think, in some ways, this is a great example because it shows how it's so immediate, the impact of this substance that, again, was legally added to food with no oversight. In some ways it's a misleading example because I think so many of the substances in food, it's not going to be so clear and so immediate. It's going to be year over year, decade over decade as part of a full diet that these are causing cardiovascular risk, thyroid disease, cancer risk, those kinds of things. I'd love to hear from either of you about this. Why is FDA falling down on the job so badly? Is it that they don't have the money to do the necessary testing? Do they not have the authority? Is there not the political will to do this? Is there complete caving into the food industry? Just let them do what they want and we're going let it go? Jennifer: All of the above? Everything you just said? It's all of the above. Emily: Jen, do you wanna talk about the money side? Because that sort of gets to the genesis of the article we worked on, which was like maybe there's a creative solution to that piece. Yes, I'd love to hear about that because I thought that was a very creative thing that you guys wrote about in your paper. That there would be an industry user fee to help produce this oversight. Tell us what you had in mind with that. And then then convince me that FDA would appropriately use this oversight and do its job. So, the idea in the paper was proposing a comprehensive user fee program for the food branch of the FDA. The FDA currently collects user fees for all of human drugs, animal drugs, medical devices, etc. With Tobacco, it's a hundred percent funded by user fees. But food, it only gets 1% of its funding through user fees. And it's important to note user fees fund processes. They don't fund outcomes. It's not like a bribe. And the idea behind user fees and why industry sometimes supports them is actually to bring predictability to the regulatory state. It brings efficiency to reviews. And then this all allows the industry to anticipate timelines so they can bring products to market and know when they're going be able to do it. In the food context, for example, the FDA is required to respond to those food additives petitions that we talked about within 180 days. But they can't respond in time. And they have a lot of timelines that are required of them in the food context that they can't meet. They can't meet their timelines because they're so underfunded. So, we proposed a comprehensive user fee. But one of the main reasons that we think a user fee is important is to address the pre-market issues that I talked about and the post-market issues that Emily talked about. In order to close that GRAS loophole, first of all, FDA needs to either reevaluate its authorities or Congress needs to change its authorities. But it would need resources to be able to do something pre-market. Some of the ideas we had was that the user fee would fund some type of either pre-market review, pre-market notification, or even just a pre-market system where the FDA determines whether a proposed ingredient should go through the GRAS avenue, or through food additive petition. So at least that there will be some type of pre-market oversight over all the ingredients in the food supply. And then also the FDA is so severely lacking in any type of comprehensive post-market into play, they would have the resources to engage in a more comprehensive post-market review for all the ingredients. Could you see a time, and I bring this up because of lawsuits against the food industry for some of these additives that are going on now. The state attorney's generals are starting to get involved, and as you said, Emily, the some states are taking legislative action to ban certain things in the food supply. Do you think there could come a time when the industry will come to government pleading to have a user fee like this? To provide some standardization across jurisdictions, let's say? So, there's two things. The first is Congress has to pass the user fee, and historically, actually, industry has done exactly what you said. They have gone to Congress and said, you know what? We want user fees because we want a streamlined system, and we want to be able to know when we're bringing products to market. The problem in the context of food for the issues we're talking about is that right now they can use the GRAS loophole. So, they have very little incentive to ask for user fees if they can bring all their ingredients into the market through the GRAS loophole. There are other areas where a user fee is very relevant, such as the infant formula 90 day pre-market notification, or for different claims like health claims. They might want user fees to speed those things up, but in terms of the ingredients, unless we close the GRAS loophole, they'd have little incentive to actually come to the table. But wouldn't legal liability change that? Let's say that some of these lawsuits are successful and they start having to pay large settlements or have the State Attorneys General, for example, come down on them for these kinds of things. If they're legally liable for harm, they're causing, they need cover. And wouldn't this be worth the user fee to provide them cover for what they put in the food supply? Yes, it's great to have the flexibility to have all these things get through the loophole, but it'd be great as well to have some cover so you wouldn't have so much legal exposure. But you guys are the lawyers, so I'm not sure it makes sense. I think you're right that there are forces combining out in the world that are pushing for change here. And I think it's hard to disentangle how much is it that industry's pushing for user fees versus right now I think more willing to consider federal regulatory changes by either FDA or by Congress. At the state level this is huge. There's now becoming a patchwork across states, and I think that is really difficult for industry. We were tracking this year 93 bills in 35 states that either banned an additive in the general public, banned it in schools. Banned ultra-processed foods, which most of the states, interestingly, have all defined differently. But where they have had a definition, it's been tied to various different combinations of additives. So that's going on. And then I think you're right, that the legal cases moving along will push industry to really want clear and better standards. I think there's a good question right now around like how successful will some of these efforts be? But  what we are seeing is real movement, both in FDA and in Congress, in taking action on this. So interestingly, the Health Affairs piece that we worked on was out this spring. But we had this other piece that came out last fall and felt like we were screaming into the void about this is a problem generally recognized as safe as a really big issue. And suddenly that has really changed. And so, you know, in March FDA said they were directed by RFK (Robert F. Kennedy), by HHS (Health and Human Services) to really look into changing their rule on generally recognized as safe. So, I know that's underway. And then in Congress, multiple bills have been introduced. And I know there are several in the works that would address additives and specifically, generally recognized as safe. There's this one piece going on, which is there's forces coalescing around some better method of regulation. I think the question's really going to also be like, will Congress give adequate resources? Because there is also another scenario that I'm worried about that even if FDA said we're going now require at least notification for every substance that's generally recognized as safe. It's a flood of substances. And they just, without more resources, without more staff devoted to this, there's no way that they're going to be able to wade through that. So, I think that either the resources need to come from user fees, or at least partially from user fees, from more appropriations and I think, In my opinion, they are able to do that on their own. Even given where current administrative law stands. Because I think it's very clear that the gist of the statute is that FDA should be overseeing additives. And I think a court would say this is allowing everything to instead go through this alternative pathway. But I really think FDA's going to need resources to manage this. And perhaps more of a push from Congress to make sure that they really do it to the best of their ability. I was going to say there's also an alternative world where we don't end up spending any of these resources, and they require the industry just to disclose all the ingredients they've added to food and put it on a database. This is like low hanging fruit, not very expensive, doesn't require funding. And then the NGOs, I hope, would go to work and say, look at this. There is no safety data for these ingredients. You know, because right now we just can't rely on FDA to do anything unless they get more funding to do something. So, if FDA doesn't get funding, then maybe this database where houses every ingredient that's in the food supply as a requirement could be a low resource solution. Jennifer, I'll come back to you in a minute because I'd like to ask how worried should we be about all this stuff that's going into food. But Emily, let me ask you first, does FDA have the authority to do what it needs to do? Let's say all of a sudden that your wish was granted and there were user fees would it then be able to do what needs to be done? I think certainly to be able to charge these user fees in almost all areas, it right now doesn't have that authority, and Congress would need to act. There's one small area which is within the Food Safety Modernization Act for certain types of like repeat inspections or recalls or there's a couple other. FDA isn't charging fees right now because they haven't taken this one step that they need to take. But they do have the authority if they just take those steps. But for everything else, Congress has to act. I think the real question to me is because we now know so many of these substances are going through this GRAS pathway, the question is really can they do everything they need to do on their own to close that loophole? And again, my opinion is Congress could make it clear and if Congress were to act, it would be better. Like they could redefine it in a way that was much more clear that we are drawing a real line. And most things actually should be on the additive side of the line rather than the generally recognized as safe side of the line. But even with their current authority, with the current definition, I think FDA could at least require notification because they're still drawing a line between what's required for additives, which is a very lengthy pre-market process with, you know, a notice and comment procedure and all of these things. My take is FDA do what you can do now. Let's get the show on the road. Let's take steps here to close up the loophole. And then Congress takes time. But they definitely can even strengthen this and give a little more, I think, directives to FDA as to how to make sure that this loophole doesn't recur down the line. In talks that I've given recently, I've shown an ingredient list from a food that people will recognize. And I ask people to try to guess what that food is from its ingredient list. This particular food has 35 ingredients. You know, a bunch of them that are very hard to pronounce. Very few people would even have any idea at all what those ingredients do. There's no sense at all about how ingredient number 17 would interact with ingredient 31, etc. And it just seems like it's complete chaos. And I don't want to take you guys outside your comfort zone because your backgrounds are law. But Jennifer, let me ask you this. You have a background in public health as well. There are all kinds of reasons to be worried about this, aren't there? There are the concerns about the safety of these things, but then there's a concern about what these ultra-processed ingredients do to your metabolism, your ability to control your weight, to regulate your hunger and things like that. It sounds this is a really important thing. And it's affecting almost everybody in the country. The percentage of calories that are now coming from ultra-processed foods is over 50% in both children and adults. So it sounds like there's really reason to worry. Would you agree? Yes. And also, the FDA is supposed to be overseeing the cumulative effects of the ingredients and it doesn't actually enforce that regulation. Its own regulation that it's supposed to evaluate the cumulative effects. It doesn't actually enforce this. So by cumulative effects do you mean the chronic effects of long term use? And, having these ingredients across multiple products within one person's consumption. Also, the FDA doesn't look at things like the effect on the gut microbiome, neurotoxicity, even cancer risk, even though they're supposed to, they say that if something is GRAS, they don't need to look at it because cancer risk is relegated only to food additives. So here we're at a real issue, right? Because if everything's entering through the GRAS loophole, then they're not looking at carcinogen effects. So, I think there is a big risk and as Emily had said earlier, that these are sometimes long-term risks versus that acute example of tara flour that we don't know. And we do know from the science, both older and emerging science, that ultra-processed food has definite impact on not only consumption, increased consumption, but also on diet related diseases and other health effects. And by definition what we're talking about here are ultra-processed foods. These ingredients are only found in ultra-processed foods. So, we do know that there is cause for concern. It's interesting that you mentioned the microbiome because we've recorded a cluster of podcasts on the microbiome and another cluster of podcasts on artificial sweeteners. Those two universes overlap a good bit because the impact of the artificial sweeteners on some of them, at least on the microbiome, is really pretty negative. And that's just one thing that goes into these foods. It really is pretty important. By the way, that food with 35 ingredients that I mentioned is a strawberry poptart. Jennifer: I know that answer! Emily: How do you know that? Jennifer: Because I've seen Kelly give a million talks. Yes, she has. Emily: I was wondering, I was like, are we never going to find out? So the suspense is lifted. Let me end with this. This has been highly instructive, and I really appreciate you both weighing in on this. So let me ask each of you, is there reason to be optimistic that things could improve. Emily, I'll start with you. So, I've been giving this talk the past few months that's called basically like Chronic Disease, Food Additives and MAHA, like What Could Go Right and What Could Go Wrong. And so, I'm going give you a very lawyerly answer, which is, I feel optimistic because there's attention on the issue. I think states are taking action and there's more attention to this across the political spectrum, which both means things are happening and means that the narrative changing, like people are getting more aware and calling for change in a way that we weren't seeing. On the flip side, I think there's a lot that could go wrong. You know, I think some of the state bills are great and some of them are maybe not so great. And then I think this administration, you have an HHS and FDA saying, they're going to take action on this in the midst of an administration that's otherwise very deregulatory. In particular, they're not supposed to put out new regulations if they can get rid of 10 existing ones. There are some things you can do through guidance and signaling, but I don't think you can really fix these issues without like real durable legislative change. So, I'm sorry to be one of the lawyers here. I think the signals are going in the right direction, but jury is out a little bit on how well we'll actually do. And I hope we can do well given the momentum. What do you think, Jennifer? I agree that the national attention is very promising to these issues. The states are passing laws that are shocking to me. That Texas passing a warning label law, I would never have thought in the history of the world, that Texas would be the one to pass a warning label law. They're doing great things and I actually have hope that something can come of this. But I am concerned at the federal level of the focus on deregulation may make it impossible. User fees is an example of where they won't have to regulate, but they could provide funding to the FDA to actually act in areas that it has the authority to act. That is one solution that could actually work under this administration if they were amenable to it. But I also think in some ways the states could save us. I worry, you know, Emily brought up the patchwork, which is the key term the industry uses to try to get preemption. I do worry about federal preemption of state actions. But the states right now are the ones saving us. California is the first to save the whole nation. The food industry isn't going to create new food supply for California and then the rest of the country. And then it's the same with other states. So, the states might be the ones that actually can make some real meaningful changes and get some of the most unsafe ingredients out of the food supply, which some of the states have now successfully done. Bios Emily Broad Leib is a Clinical Professor of Law, Director of Harvard Law School Center for Health Law and Policy Innovation, and Founding Director of the Harvard Law School Food Law and Policy Clinic, the nation's first law school clinic devoted to providing legal and policy solutions to the health, economic, and environmental challenges facing our food system. Working directly with clients and communities, Broad Leib champions community-led food system change, reduction in food waste, food access and food is medicine interventions, and equity and sustainability in food production. Her scholarly work has been published in the California Law Review, Wisconsin Law Review, Harvard Law & Policy Review, Food & Drug Law Journal, and Journal of Food Law & Policy, among others. Professor Jennifer Pomeranz is a public health lawyer who researches policy and legal options to address the food environment, obesity, products that cause public harm, and social injustice that lead to health disparities. Prior to joining the NYU faculty, Professor Pomeranz was an Assistant Professor at the School of Public Health at Temple University and in the Center for Obesity Research and Education at Temple. She was previously the Director of Legal Initiatives at the Rudd Center for Food Policy and Obesity at Yale University. She has also authored numerous peer-reviewed and law review journal articles and a book, Food Law for Public Health, published by Oxford University Press in 2016. Professor Pomeranz leads the Public Health Policy Research Lab and regularly teaches Public Health Law and Food Policy for Public Health.

Welcome to Ozempic Weightloss Unlocked, the podcast where we bring you the latest news and honest insights about Ozempic, its medical uses, and how it's shaping lives and health choices today.Right now, Ozempic, whose active ingredient is semaglutide, is grabbing headlines for two main reasons. First, its original role as a once-weekly injectable for controlling blood sugar in type 2 diabetes. And second, its growing off-label use for weight management, even in people without diabetes. According to recent studies, those using Ozempic for type 2 diabetes typically experience around six to seven percent body weight reduction. Meanwhile, newer research reveals that people seeking weight loss alone — even those without diabetes — can see average losses up to fifteen percent of their starting body weight over about 68 weeks. That data comes from high-profile clinical trials and is supported by publications like Drugs.com and Indiana University blogs.The main way Ozempic works is by mimicking a gut hormone to boost insulin and slow digestion, which curbs appetite and helps regulate blood sugar. Many people using Ozempic report feeling fuller after smaller meals and noticing dramatically reduced cravings, especially for snacks and sweets. Patients often say the weight loss feels different compared to past diets, as it's less about constant hunger battles and more about natural appetite control.What about safety? Like any medication, Ozempic has trade-offs. The most common side effects are mild to moderate stomach issues—think nausea, diarrhea, or constipation, especially as your body adjusts to the drug. There's also an increase in reports of “Ozempic face,” a phrase describing loose skin and more prominent wrinkles, although experts clarify this is from rapid weight loss rather than the drug itself. Some people experience hair thinning and muscle loss, again tied to losing weight quickly. According to guidance from the University of Kentucky and Kentucky Health News, these risks are present with most major weight loss methods, not just with Ozempic.Rare but serious side effects have surfaced and deserve attention. Investigations and lawsuits in 2025 have highlighted complications like gastroparesis — that's a severely delayed emptying of the stomach — and a condition called non-arteritic anterior ischemic optic neuropathy, which affects vision. There's also a small risk of gallstones, gallbladder issues, pancreatitis, dehydration-related kidney problems, and concerns about thyroid C-cell tumors, though that last risk is still being studied mostly in animals.Ozempic is not the only medication in the spotlight. Wegovy, also containing semaglutide but at higher doses, is approved specifically for chronic weight management and typically results in even more robust weight loss, often around fifteen percent. Meanwhile, new drugs like tirzepatide, marketed as Zepbound or Mounjaro, are now showing even greater effect sizes. According to New England Journal of Medicine coverage summarized by the University of Kentucky, tirzepatide can lead to an average of twenty percent or more body weight lost in some patients, far outpacing Ozempic and making headlines as possibly the most effective approved injection to date.With all this buzz, it's crucial for listeners to have honest conversations with their health providers. Ozempic and newer medications are changing expectations around weight loss, but they also bring a new set of considerations. Not every listener will respond the same way, and long-term effects are still being studied.That wraps up this episode of Ozempic Weightloss Unlocked. Thank you for tuning in and letting us help illuminate the facts behind the headlines. Do not forget to subscribe to stay updated on the most important developments. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

A randomized controlled trial published in the New England Journal of Medicine confirmed what some cancer specialists have long hoped: physical activity can prolong cancer patients' lives. Last week, we heard from the senior author of that study, medical oncologist Christopher Booth. In this episode, we hear from an exercise physiologist who has been helping […]

On this week's Tech Nation, Frontline Stories from Ukraine's International Legion with Military Historian Dr. Shannon Monaghan, for Type I diabetics, the New England Journal of Medicine publishes early success with Sana Biotechnology's engineered insulin-producing cells without immunosuppressant drugs, and Daniel Kraft reports in on the BioTech Nation session from NextMed Health 2025.

On this week's Tech Nation, Frontline Stories from Ukraine's International Legion with Military Historian Dr. Shannon Monaghan, for Type I diabetics, the New England Journal of Medicine publishes early success with Sana Biotechnology's engineered insulin-producing cells without immunosuppressant drugs, and Daniel Kraft reports in on the BioTech Nation session from NextMed Health 2025.

On this week's Tech Nation, Frontline Stories from Ukraine's International Legion with Military Historian Dr. Shannon Monaghan, for Type I diabetics, the New England Journal of Medicine publishes early success with Sana Biotechnology's engineered insulin-producing cells without immunosuppressant drugs, and Daniel Kraft reports in on the BioTech Nation session from NextMed Health 2025.

[01:02:08] Meta AI Grooming ChildrenDiscussion of Meta's chatbot seducing vulnerable users and grooming children, raising alarms over how AI is weaponized for control. [01:10:12] Congress Uses Crisis to Push Digital IDCriticism of Senators using Meta's scandal to advance online ID systems instead of stopping child exploitation. [01:16:56] Larry Fink & BlackRock Control WEFAnalysis of BlackRock's Larry Fink taking over World Economic Forum power, enforcing ESG/DEI agendas, and forcing global corporate compliance. [01:43:07] Trump & Ukraine Peace DealCoverage of Trump's position on Ukraine peace negotiations, skepticism over EU/NATO motives, and fears of engineered perpetual war. [01:55:04] U.S./UK Boots on the GroundTrump assures “no American boots” in Ukraine but hints at air support; UK pushes to deploy ground forces immediately. [02:06:25] Vaccine-Autism Study ExposedChildren's Health Defense scientists challenge a 2002 New England Journal of Medicine study dismissing autism links, calling its math flawed and data manipulated. [02:16:31] Lawsuit Against CDC Over 72-Dose ScheduleA major lawsuit highlights the CDC's failure to test the combined childhood vaccine schedule, alleging constitutional violations and industry capture. [02:23:21] Texas Sues Eli Lilly for BriberyAttorney General Ken Paxton sues the pharma giant for bribing doctors to push high-profit drugs, drawing parallels to the opioid crisis. [02:32:13] Mercury Fillings & Global BansExposure of the American Dental Association's ties to toxic mercury amalgam fillings, contrasted with EU and global bans ignored by U.S. regulators. [02:55:23] Election Rigging & Gerrymandering TeaserClosing segment transitions into election rigging and gerrymandering, previewing corruption on both political sides. [03:01:12] Gerrymandering & Rigged ElectionsDiscussion on redistricting battles in California and Texas, showing how both parties manipulate maps to lock in control and eliminate real voter choice. [03:10:06] Usury: Biblical Condemnation & Modern ExploitationShift to economic corruption, exposing how usury was once banned in Christian and civil law, but now thrives through credit cards, mortgages, and payday loans. [03:47:14] Trump, Heaven & Zionist Third Temple PlansTrump claims foreign policy wins could earn him heaven; contrasted with Zionist efforts to breed red heifers and rebuild the Third Temple, seen as delusional legalism. [03:57:00] Zionism, Prophecy & Final WarningsClosing critique of Zionist attempts to “force God's hand” in prophecy, with warnings against false gospels and misplaced faith in political or religious schemes. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

[01:02:08] Meta AI Grooming ChildrenDiscussion of Meta's chatbot seducing vulnerable users and grooming children, raising alarms over how AI is weaponized for control. [01:10:12] Congress Uses Crisis to Push Digital IDCriticism of Senators using Meta's scandal to advance online ID systems instead of stopping child exploitation. [01:16:56] Larry Fink & BlackRock Control WEFAnalysis of BlackRock's Larry Fink taking over World Economic Forum power, enforcing ESG/DEI agendas, and forcing global corporate compliance. [01:43:07] Trump & Ukraine Peace DealCoverage of Trump's position on Ukraine peace negotiations, skepticism over EU/NATO motives, and fears of engineered perpetual war. [01:55:04] U.S./UK Boots on the GroundTrump assures “no American boots” in Ukraine but hints at air support; UK pushes to deploy ground forces immediately. [02:06:25] Vaccine-Autism Study ExposedChildren's Health Defense scientists challenge a 2002 New England Journal of Medicine study dismissing autism links, calling its math flawed and data manipulated. [02:16:31] Lawsuit Against CDC Over 72-Dose ScheduleA major lawsuit highlights the CDC's failure to test the combined childhood vaccine schedule, alleging constitutional violations and industry capture. [02:23:21] Texas Sues Eli Lilly for BriberyAttorney General Ken Paxton sues the pharma giant for bribing doctors to push high-profit drugs, drawing parallels to the opioid crisis. [02:32:13] Mercury Fillings & Global BansExposure of the American Dental Association's ties to toxic mercury amalgam fillings, contrasted with EU and global bans ignored by U.S. regulators. [02:55:23] Election Rigging & Gerrymandering TeaserClosing segment transitions into election rigging and gerrymandering, previewing corruption on both political sides. [03:01:12] Gerrymandering & Rigged ElectionsDiscussion on redistricting battles in California and Texas, showing how both parties manipulate maps to lock in control and eliminate real voter choice. [03:10:06] Usury: Biblical Condemnation & Modern ExploitationShift to economic corruption, exposing how usury was once banned in Christian and civil law, but now thrives through credit cards, mortgages, and payday loans. [03:47:14] Trump, Heaven & Zionist Third Temple PlansTrump claims foreign policy wins could earn him heaven; contrasted with Zionist efforts to breed red heifers and rebuild the Third Temple, seen as delusional legalism. [03:57:00] Zionism, Prophecy & Final WarningsClosing critique of Zionist attempts to “force God's hand” in prophecy, with warnings against false gospels and misplaced faith in political or religious schemes. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

This is a hybrid heart disease risk factor post of a podcast with Prof Bruce Lanphear on lead and a piece I was asked to write for the Washington Post on risk factors for heart disease.First, the podcast. You may have thought the problem with lead exposure was circumscribed to children, but it's a much bigger issue than that. I'll concentrate on the exposure risk to adults in this interview, including the lead-estrogen hypothesis. Bruce has been working on the subject of lead exposure for more than 30 years. Let me emphasize that the problem is not going away, as highlighted in a recent New England Journal of Medicine piece on lead contamination in Milwaukee schools, “The Latest Episode in an Ongoing Toxic Pandemic.”Transcript with links to the audio and citationsEric Topol (00:05):Well, hello. This is Eric Topol with Ground Truths, and I'm very delighted to welcome Professor Bruce Lanphear from Simon Fraser University in British Columbia for a very interesting topic, and that's about lead exposure. We tend to think about lead poisoning with the Flint, Michigan, but there's a lot more to this story. So welcome, Bruce.Bruce Lanphear (00:32):Thank you, Eric. It's great to be here.Eric Topol (00:33):Yeah. So you had a New England Journal of Medicine (NEJM) Review in October last year, which was probably a wake up to me, and I'm sure to many others. We'll link to that, where you reviewed the whole topic, the title is called Lead Poisoning. But of course it's not just about a big dose, but rather chronic exposure. So maybe you could give us a bit of an overview of that review that you wrote for NEJM.Bruce Lanphear (01:05):Yeah, so we really focused on the things where we feel like there's a definitive link. Things like lead and diminished IQ in children, lead and coronary heart disease, lead and chronic renal disease. As you mentioned, we've typically thought of lead as sort of the overt lead poisoning where somebody becomes acutely ill. But over the past century what we've learned is that lead is one of those toxic chemicals where it's the chronic wear and tear on our bodies that catches up and it's at the root of many of these chronic diseases that are causing problems today.Eric Topol (01:43):Yeah, it's pretty striking. The one that grabbed me and kind of almost fell out of my chair was that in 2019 when I guess the most recent data there is 5.5 million cardiovascular deaths ascribed to relatively low levels, or I guess there is no safe level of lead exposure, that's really striking. That's a lot of people dying from something that cardiology and medical community is not really aware of. And there's a figure 3 [BELOW] that we will also show in the transcript, where you show the level where you start to see a takeoff. It starts very low and by 50 μg/liter, you're seeing a twofold risk and there's no threshold, it keeps going up. How many of us do you think are exposed to that type of level as adults, Bruce?Bruce Lanphear (02:39):Well, as adults, if we go back in time, all of us. If you go back to the 1970s when lead was still in gasoline, the median blood lead level of Americans was about 13 to 15 µg/dL. So we've all been exposed historically to those levels, and part of the reason we've begun to see a striking decline in coronary heart disease, which peaked in 1968. And by 1978, there was a 20% decline, 190,000 more people were alive than expected. So even in that first decade, there was this striking decline in coronary heart disease. And so, in addition to the prospective studies that have found this link between an increase in lead exposure and death from cardiovascular disease and more specifically coronary heart disease. We can look back in time and see how the decline in leaded gasoline led to a decline in heart disease and hypertension.Eric Topol (03:41):Yeah, but it looks like it's still a problem. And you have a phenomenal graph that's encouraging, where you see this 95% reduction in the lead exposure from the 1970s. And as you said, the factors that can be ascribed to like getting rid of lead from gasoline and others. But what is troubling is that we still have a lot of people that this could be a problem. Now, one of the things that was fascinating is that you get into that herbal supplements could be a risk factor. That we don't do screening, of course, should we do screening? And there's certain people that particularly that you consider at high risk that should get screened. So I wasn't aware, I mean the one type of supplements that you zoomed in on, how do you say it? Ayurvedic?Supplements With LeadBruce Lanphear (04:39):Oh yeah. So this is Ayurvedic medicine and in fact, I just was on a Zoom call three weeks ago with a husband and wife who live in India. The young woman had taken Ayurvedic medicine and because of that, her blood lead levels increased to 70 µg/dL, and several months later she was pregnant, and she was trying to figure out what to do with this. Ayurvedic medicine is not well regulated. And so, that's one of the most important sources when we think about India, for example. And I think you pointed out a really important thing is number one, we don't know that there's any safe level even though blood lead levels in the United States and Europe, for example, have come down by over 95%. The levels that we're exposed to and especially the levels in our bones are 10 to 100 times higher than our pre-industrial ancestors.Bruce Lanphear (05:36):So we haven't yet reached those levels that our ancestors were exposed to. Are there effects at even lower and lower levels? Everything would suggest, we should assume that there is, but we don't know down below, let's say one microgram per deciliter or that's the equivalent of 10 parts per billion of lead and blood. What we also know though is when leaded gasoline was restricted in the United States and Canada and elsewhere, the companies turned to the industrializing countries and started to market it there. And so, we saw first the epidemic of coronary heart disease in the United States, Canada, Europe. Then that's come down over the past 50 years. At the same time, it was rising in low to middle income countries. So today over 95% of the burden of disease from lead including heart disease is found in industrializing countries.Eric Topol (06:34):Right. Now, it's pretty striking, of course. Is it true that airlines fuel is still with lead today?Bruce Lanphear (06:45):Well, not commercial airlines. It's going to be a small single piston aircraft. So for example, when we did a study down around the Santa Clara County Airport, Reid-Hillview, and we can see that the children who live within a half mile of the airport had blood lead levels about 10% higher than children that live further away. And the children who live downwind, 25% higher still. Now, nobody's mapped out the health effects, but one of the things that's particularly troubling about emissions from small aircraft is that the particle size of lead is extraordinarily small, and we know how nanoparticles because they have larger surface area can be more problematic. They also can probably go straight up into the brain or across the pulmonary tissues, and so those small particles we should be particularly worried about. But it's been such a long journey to try to figure out how to get that out of aircraft. It's a problem. The EPA recognized it. They said it's an endangerment, but the industry is still pushing back.Eric Topol (07:55):Yeah, I mean, it's interesting that we still have these problems, and I am going to in a minute ask you what we can do to just eradicate lead as much as possible, but we're not there yet. But one study that seemed to be hard to believe that you cited in the review. A year after a ban leaded fuel in NASCAR races, mortality from coronary heart disease declined significantly in communities near racetracks. Can you talk about that one because it's a little bit like the one you just mentioned with the airports?Bruce Lanphear (08:30):Yeah. Now that study particularly, this was by Alex Hollingsworth, was particularly looking at people over 65. And we're working on a follow-up study that will look at people below 65, but it was quite striking. When NASCAR took lead out of their fuel, he compared the rates of coronary heart disease of people that live nearby compared to a control group populations that live further away. And he did see a pretty striking reduction. One of the things we also want to look at in our follow-up is how quickly does that risk begin to taper off? That's going to be really important in terms of trying to develop a strategy around preventing lead poisoning. How quickly do we expect to see it fall? I think it's probably going to be within 12 to 24 months that we'll see benefits.Eric Topol (09:20):That's interesting because as you show in a really nice graphic in adults, which are the people who would be listening to this podcast. Of course, they ought to be concerned too about children and all and reproductive health. But the point about the skeleton, 95% of the lead is there and the main organs, which we haven't mentioned the kidney and the kidney injury that occurs no less the cardiovascular, the blood pressure elevation. So these are really, and you mentioned not necessarily highlighted in that graphic, but potential cognitive hit as well. You also wrote about how people who have symptoms of abdominal pain, memory impairment, and high blood pressure that's unexplained, maybe they should get a blood level screening. I assume those are easy to get, right?Bruce Lanphear (10:17):Oh yeah, absolutely. You can get those in any hospital, any clinic across the country. We're still struggling with having those available where it's most needed in the industrializing countries, but certainly available here. Now, we don't expect that for most people who have those symptoms, lead poisoning is going to be the cause, right. It'd still be unusual unless you work in an industry, for example, smelting batteries to recycle them. We don't expect it to be real common, and we're not even sure, Eric, whether we should be doing widespread screening. If I looked at this as a population scientist, the real focus should be on identifying the sources. We mostly know where those are here and radically moving it down. Getting rid of the lead service lines, which was such a big part of what President Biden was doing, and it was perfect. For every dollar invested to reduce lead exposure from those lead service lines. Ronnie Levin at Harvard said there'd be a 35-fold return in cost, benefits really, and this has always been true, that reducing lead exposure throughout the past 40 years has always been shown to be amazingly cost beneficial. The problem is operating within a free market health system, even though there's tremendous social benefits, that benefit isn't going to be monetized or privatized. And so, who's going to make those decisions? We hope our government is, but that doesn't always play out.Eric Topol (11:52):Well. What's interesting is, as opposed to the problems we have today that are prominent such as the microplastic, nanoplastics, the air pollution, the forever chemicals, that just keep getting worse, I mean, they are just cumulative. This one, there was tremendous improvement, but it's still not enough. And I guess you're zooming in on the lead lines. That'd be the most important thing to work on today. Another thing that has come up, there's been trials, as you may I'm sure, because all over this field of chelation, there's a trial that was run by the NIH, supported by NH that looked at chelation to prevent coronary disease. Is there any evidence that people who have a problem with lead would benefit from chelation therapy?Bruce Lanphear (12:44):Well, there's two major studies that have been done, and Tony Lamas was in charge of both of them. The first one Trial to Assess Chelation Therapy (TACT) study, it was a randomized controlled trial, not intended specifically to focus on lead, but rather it was to look at sort of this alternative therapy. They found significant benefits about an 18% reduction in subsequent cardiac events. That led to a second study that was just published last year, and it was focused on people who had diabetes. They saw some benefit, but it wasn't significant. So whether that's because there wasn't enough variability and exposure, it's not entirely clear, but we've seen this with lead in IQ deficits in kids where we can show that we can reduce blood lead levels. But ultimately what tends to happen is once you've taken lead out of the blood, some of it's released again from the bone, but you still have all that lead in the bone that's there. You get some of it out, but you're not going to get the bulk of it out.The Lead-Estrogen HypothesisEric Topol (13:47):Right. It's a reservoir that's hard to reckon with. Yeah. Now another thing, you have a Substack that is called Plagues, Pollution & Poverty, and you wrote a really provocative piece in that earlier and April called How Estrogen Keeps Lead - and Heart Attacks - in Check, and basically you got into the lead estrogen hypothesis.Eric Topol (14:10):Can you enlighten us about that?Bruce Lanphear (14:12):Yeah. A lot of the seminal work in this area was done by Ellen Silbergeld, who's a brilliant and somewhat peculiar toxicologist and Ellen for years, I focused on childhood lead exposure, and for years Ellen would tell me, almost demolish me for not studying adults. And because she had found back in 1988 that as women go into menopause, their blood lead levels spike increased by about 30%, and that's where most of our lead is stored is in our bone. And so, as I was thinking about this, it all became clear because blood lead levels in boys and girls is about the same. It's comparable up until menarche, and then girls young women's blood leads fall by about 20%. And they stay 20% lower throughout the reproductive years until menopause. And especially during those first few years around menopause, perimenopause, you see fairly striking increases in the weakening of the bone and blood lead levels.Bruce Lanphear (15:19):So that might very well help to explain why estrogen is protected, because what happens is throughout the reproductive life, women are losing a little bit of lead every month. And estrogen is at its lowest during that time, and that's going to be when blood lead is at its highest because estrogen pushes lead into the bone. Not only that, women lose lead into the developing fetus when they're pregnant. So what Ellen found is that there was less of a spike around menopause for the women that had three or four pregnancies because they had offloaded that into their babies. So all of this, if you put it together, and this is of course in a very short note of it, you can see that lead increases dyslipidemia, it leads to tears in the endothelium of the arterial wall, it's going to increase thrombosis. All of these things that we think of as the classic atherosclerosis. Well, what estrogen does is the opposite of those. It decreases dyslipidemia, it repairs the arterial endothelial wall. So how much of it is that estrogen is protective, and how much is it that it's moving lead out of the system, making it less biologically available?Eric Topol (16:46):Yeah, I know. It's really interesting. Quite provocative. Should be followed up on, for sure. Just getting to you, you're a physician and epidemiologist, MD MPH, and you have spent your career on this sort of thing, right? I mean, is your middle name lead or what do you work on all the time?Bruce Lanphear (17:09):Yeah, I've been doing this for about 30 years, and one of my mentors, Herb Needleman spent 40 years of his career on it. And in some ways, Eric, it seems to me particularly in these very difficult entrenched problems like lead, we don't have any pharmaceutical company reaching out to us to promote what we do. We've got industry trying to squash what we do.Bruce Lanphear (17:35):It really does take a career to really make a dent in this stuff. And in a way, you can look at my trajectory and it is really following up on what Herb Needleman did and what Clare Patterson did, and that was finding the effects at lower and lower levels. Because what we do with lead and most other toxic chemicals, the ones that don't cause cancer, is we assume that there's a safe level or threshold until we prove otherwise. And yet when you look at the evidence, whether it's about asbestos and mesothelioma, air pollution and cardiovascular mortality, lead and cardiovascular mortality, benzene and leukemia, none of those exhibit a threshold. In some cases, the risks are steepest proportionately at the lowest measurable levels, and that really raises some tremendous challenges, right? Because how are we going to bring air pollution or lead down to zero? But at the same time, it also provides these tremendous opportunities because we know that they're causing disease. We know what the sources are. If we could only bring about the political will to address them, we could prevent a lot of death, disease, and disability. I mean, about 20% of deaths around the world every year are from air pollution, lead, and other toxic chemicals, and yet the amount of money we invest in them is just paltry compared to what we invest in other things. Which is not to pit one against the other, but it's to say we haven't invested enough in these.Eric Topol (19:14):No, absolutely. I think your point, just to make sure that it's clear, is that even at low levels, this is of course where most of the population exposure would be, and that's why that's so incriminating. Now, one of the things I just want to end up with is that we know that these are tiny, tiny particles of lead, and then the question is how they can synergize and find particulate matter of air pollution in the nanoplastic, microplastic story and binding to forever chemicals, PFAS. How do you process all that? Because it's not just a single hit here, it's also the fact that there's ability to have binding to the other environmental toxins that are not going away.Bruce Lanphear (20:10):That's right. And in a way, when we talk about lead playing this tremendous role in the rise and decline of coronary heart disease, we can't entirely separate it out, for example, from air pollution or cigarette smoke for that matter, nor plastic. So for example, with air pollution, if we look at air pollution over the past century, up until the 1980s, even into the 1990s, it was leaded, right? So you couldn't separate them. If you look at cigarette smoke, cigarette tobacco in the 1940s and 1950s was grown in fields where they used lead arsenic as an insecticide. So smokers even today have blood lead levels that are 20% higher than non-smokers, and people who are not smokers but exposed to secondhand smoke have blood lead levels 20% higher than non-smokers who aren't exposed to secondhand smoke. So in a way, we should try to tease apart these differences, but it's going to be really challenging. In a way we can almost think about them as a spectrum of exposures. Now with plastics, you can really think of plastics as a form of pollution because it's not just one thing. There's all these additives, whether it's the PFAS chemicals or lead, which is used as a stabilizer. And so, all of them really are kind of integrated into each other, which again, maybe there's some opportunity there if we really were ready to tackle.Eric Topol (21:40):And interestingly, just yesterday, it was announced by the current administration that they're stopping all the prior efforts on the forever chemicals that were initiated in the water supply. And I mean, if there's one takeaway from our discussion, it's that we have to get all over this and we're not paying enough attention to our environmental exposures. You've really highlighted spotlighted the lead story. And obviously there are others that are, instead of getting somewhat better, they're actually going in the opposite direction. And they're all tied together that's what is so striking here, and they all do many bad things to our bodies. So I don't know how, I'm obviously really interested in promoting healthy aging, and unless we get on this, we're chasing our tails, right?Bruce Lanphear (22:31):Well, I think that's right, Eric. And I was reading the tips that you'd written about in preparation for your book release, and you focused understandably on what each of us can do, how we can modify our own lifestyles. We almost need six tips about what our government should do in order to make it harder for us to become sick, or to encourage those healthy behaviors that you talked about. That's a big part of it as well. One of the things we're celebrating the hundredth anniversary. This is not really something to celebrate, but we are. The hundredth anniversary of the addition of tetraethyl lead to gasoline. And one of the key things about that addition, there was this debate because when it was being manufactured, 80% of the workers at a plant in New Jersey suffered from severe lead poisoning, and five died, and it was enough that New York City, Philadelphia and New Jersey banned tetraethyl lead.Bruce Lanphear (23:31):Then there was this convening by the US Surgeon General to determine whether it was safe to add tetraethyl lead to gasoline. One scientist, Yandell Henderson said, absolutely not. You're going to create a scourge worse than tuberculosis with slow lead poisoning and hardening of your arteries. Robert Kehoe, who represented the industry said, we know lead is toxic, but until you've shown that it's toxic when added to gasoline, you have no right to prohibit us from using it. So that is now known as the Kehoe rule, and it's relevant not only for lead, but for PFAS, for air pollution, for all these other things, because what it set as a precedent, until you've shown that these chemicals or pollution is toxic when used in commerce, you have no right to prohibit industry from using it. And that's the fix we're in.Eric Topol (24:27):Well, it sounds too much like the tobacco story and so many other things that were missed opportunities to promote public health. Now, is Canada doing any better than us on this stuff?Bruce Lanphear (24:40):In some ways, but not in others. And one of the interesting thing is we don't have standards, we have guidelines. And amazingly, the cities generally try to conform to those guidance levels. With water lead, we're down to five parts per billion. The US is sticking around with ten parts per billion, but it's not even really very, it's not enforced very well. So we are doing better in some ways, not so good in other ways. The European Union, generally speaking, is doing much better than North America.Eric Topol (25:15):Yeah, well, it doesn't look very encouraging at the moment, but hopefully someday we'll get there. Bruce, this has been a really fascinating discussion. I think we all should be thankful to you for dedicating your career to a topic that a lot of us are not up on, and you hopefully are getting us all into a state of awareness. And congratulations on that review, which was masterful and keep up the great work. Thank you.Bruce Lanphear (25:42):Thank you, Eric. I appreciate it.________________________________________________My Recommendations for Preventing Heart Disease (Markedly Truncated from Text and Graphics Provided in SUPER AGERS)Recently the Washington Post asked me for a listicle of 10 ways to prevent heart disease. I generally avoid making such lists but many people have de-subscribed to this newspaper, never subscribed, or missed the post, so here it is with links to citations:Guest column by Eric Topol, MDThe buildup of cholesterol and other substances in the wall of our arteries, known as atherosclerosis, is common. It can lead to severe plaques that narrow the artery and limit blood flow, or to a crack in the artery wall that can trigger blood clot formation, resulting in a heart attack.While we've seen some major advances in treating heart disease, it remains the leading killer in the United States, even though about 80 percent of cases are considered preventable. There are evidence-based steps you can take to stave it off. As a cardiologist, here's what I recommend to my patients.1. Do both aerobic and resistance exerciseThis is considered the single most effective medical intervention to protect against atherosclerosis and promote healthy aging. Physical activity lowers inflammation in the body. Evidence has shown that both aerobic and strength training forms of exercise are important. But only 1 in 4 Americans meet the two activity guidelines from the American Heart Association: aerobic exercise of 150 minutes per week of at least moderate physical activity, such as walking, bicycling on level ground, dancing or gardening, and strength training for at least two sessions per week, which typically translates to 60 minutes weekly.The protective benefit of exercise is seen with even relatively low levels of activity, such as around 2,500 steps per day (via sustained physical activity, not starting and stopping), and generally increases proportionately with more activity. It used to be thought that people who exercise only on the weekend — known as “weekend warriors” — put themselves in danger, but recent data shows the benefits of exercise can be derived from weekend-only workouts, too.2. Follow an anti-inflammatory dietA predominantly plant-based diet — high in fiber and rich in vegetables, fruits and whole grains, as seen with the Mediterranean diet — has considerable evidence from large-scale observational and randomized trials for reducing body-wide inflammation and improving cardiovascular outcomes.Foods rich in omega-3 fatty acids, such as salmon, also form part of a diet that suppresses inflammation. On the other hand, red meat and ultra-processed foods are pro-inflammatory, and you should limit your consumption. High protein intake of more than 1.4 grams per kilogram of body weight per day — around 95 grams for someone who is 150 pounds — has also been linked to promoting inflammation and to atherosclerosis in experimental models. That is particularly related to animal-based proteins and the role of leucine, an essential amino acid that is obtained only by diet.3. Maintain a healthy weightBeing overweight or obese indicates an excess of white adipose tissue. This kind of tissue can increase the risk of heart disease because it stores fat cells, known as adipocytes, which release substances that contribute to inflammation.In studies, we've seen that glucagon-like peptide (GLP-1) drugs can reduce inflammation with weight loss, and a significant reduction of heart attacks and strokes among high-risk patients treated for obesity. Lean body weight also helps protect against atrial fibrillation, the most common heart rhythm abnormality.4. Know and avoid metabolic syndrome and prediabetesTied into obesity, in part, is the problem of insulin resistance and metabolic syndrome. Two out of three people with obesity have this syndrome, which is defined as having three out of five features: high fasting blood glucose, high fasting triglycerides, high blood pressure, low high-density lipoprotein (HDL) and central adiposity (waist circumference of more than 40 inches in men, 35 inches in women).Metabolic syndrome is also present in a high proportion of people without obesity, about 50 million Americans. Prediabetes often overlaps with it. Prediabetes is defined as a hemoglobin A1c (a measure of how much glucose is stuck to your red blood cells) between 5.7 and 6.4 percent, or a fasting glucose between 100 and 125 milligrams per deciliter.Both metabolic syndrome and prediabetes carry an increased risk of heart disease and can be prevented — and countered — by weight loss, exercise and an optimal diet.As the glucagon-like peptide drug family moves to pills and less expense in the future, these medications may prove helpful for reducing risk in people with metabolic syndrome and prediabetes. For those with Type 2 diabetes, the goal is optimizing glucose management and maximal attention to lifestyle factors.5. Keep your blood pressure in a healthy rangeHypertension is an important risk factor for heart disease and is exceptionally common as we age. The optimal blood pressure is 120/80 mm Hg or lower. But with aging, there is often an elevation of systolic blood pressure to about 130 mm Hg, related to stiffening of arteries. While common, it is still considered elevated.Ideally, everyone should monitor their blood pressure with a home device to make sure they haven't developed hypertension. A mild abnormality of blood pressure will typically improve with lifestyle changes, but more substantial elevations will probably require medications.6. Find out your genetic riskWe now have the means of determining your genetic risk of coronary artery disease with what is known as a polygenic risk score, derived from a gene chip. The term polygenic refers to hundreds of DNA variants in the genome that are linked to risk of heart disease. This is very different from a family history, because we're a product of both our mother's and father's genomes, and the way the DNA variants come together in each of us can vary considerably for combinations of variants.That means you could have high or low risk for heart disease that is different from your familial pattern. People with a high polygenic risk score benefit the most from medications to lower cholesterol, such as statins. A polygenic risk score can be obtained from a number of commercial companies, though it isn't typically covered by insurance.I don't recommend getting a calcium score of your coronary arteries via a computed tomography (CT) scan. This test is overused and often induces overwhelming anxiety in patients with a high calcium score but without symptoms or bona fide risk. If you have symptoms suggestive of coronary artery disease, such as chest discomfort with exercise, then a CT angiogram may be helpful to map the coronary arteries. It is much more informative than a calcium score.7. Check your blood lipidsThe main lipid abnormality that requires attention is low-density cholesterol (LDL), which is often high and for people with increased risk of heart disease should certainly be addressed. While lifestyle improvements can help, significant elevation typically requires medications such as a statin; ezetimibe; bempedoic acid; or injectables such as evolocumab (Repatha), alirocumab (Praluent) or inclisiran (Leqvio). The higher the risk, the more aggressive LDL lowering may be considered.It should be noted that the use of potent statins, such as rosuvastatin or atorvastatin, especially at high doses, is linked to inducing glucose intolerance and risk of Type 2 diabetes. While this is not a common side effect, it requires attention since it is often missed from lack of awareness.A low high-density lipoprotein (HDL) cholesterol often responds to weight loss and exercise. We used to think that high HDL was indicative of “good cholesterol,” but more recent evidence suggests that is not the case and it may reflect increased risk when very high.To get a comprehensive assessment of risk via your blood lipids, it's important to get the apolipoprotein B (apoB) test at least once because about 20 percent of people have normal LDL and a high apoB.Like low HDL, high fasting triglycerides may indicate insulin resistance as part of the metabolic syndrome and will often respond to lifestyle factors.The lipoprotein known as Lp(a) should also be assessed at least once because it indicates risk when elevated. The good news is scientists are on the cusp of finally having medications to lower it, with five different drugs in late-stage clinical trials.8. Reduce exposure to environmental pollutantsIn recent years, we've learned a lot about the substantial pro-inflammatory effects of air pollution, microplastics and forever chemicals, all of which have been linked to a higher risk of heart disease. In one study, microplastics or nanoplastics in the artery wall were found in about 60 percent of more than 300 people. Researchers found a vicious inflammatory response around the plastics, and a four- to fivefold risk of heart attacks or strokes during three years of follow-up.While we need policy changes to address these toxic substances in the environment, risk can be reduced by paying attention to air and water quality using filtration or purification devices, less use of plastic water bottles and plastic storage, and, in general, being much more aware and wary of our pervasive use of plastics.9. Don't smoke This point, it should be well known that cigarette smoking is a potent risk factor for coronary artery disease and should be completely avoided.10. Get Good SleepAlthough we tend to connect sleep health with brain and cognitive function, there's evidence that sleep regularity and quality are associated with less risk of heart disease. Regularity means adhering to a routine schedule as much as possible, and its benefit may be due to our body's preference for maintaining its circadian rhythm. Sleep quality — meaning with fewer interruptions — and maximal deep sleep can be tracked with smartwatches, fitness bands, rings or mattress sensors.Sleep apnea, when breathing stops and starts during sleep, is fairly common and often unsuspected. So if you're having trouble sleeping or you snore loudly, talk to your doctor about ruling out the condition. Testing for sleep apnea can involve checking for good oxygen saturation throughout one's sleep. That can be done through a sleep study or at home using rings or smartwatches that include oxygen saturation in their sensors and body movement algorithms that pick up disturbed breathing.Eric Topol, MD, is a cardiologist, professor and executive vice president of Scripps Research in San Diego. He is the author of “Super Agers: An Evidence-Based Approach to Longevity” and the author of Ground Truths on Substack.*********************°°°°°°°°°°°°°°°°°°°°Thanks to many of you Ground Truths subscribers who helped put SUPER AGERS on the NYT bestseller list for 4 weeks.Here are 2 recent, informative, and fun conversations I had on the topicMichael Shermer, The SkepticRuss Roberts, EconTalk I'm also very appreciative for your reading and subscribing to Ground Truths.If you found this interesting PLEASE share it!That makes the work involved in putting these together especially worthwhile.All content on Ground Truths—its newsletters, analyses, and podcasts, are free, open-access.Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don't hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past three years. Just a week ago we just had nearly 50 interns (high school, college and medical students) present posters of the work they did over the summer and it was exhilarating! Some photos below Get full access to Ground Truths at erictopol.substack.com/subscribe

Today we unpack some of healthcare's succession and retirement trends Doctors should know about when considering hiring, replacing and leaving medicine better than how it found you! Craig Fowler, Founder & President of the Athenic Group, which helps Hospitals, Medical Practice Owners, UCs, Nurses, PAs, Doctors and others solve their healthcare recruiting challenges through dedicated Physician Search and the training and development of your recruiting the right medical staff to fit in well in your practice environment and remain committed for years to come. LISTEN TO FULL PODCAST EPISODE Craig is a 20+ year veteran of the physician recruiting industry; including holding senior leadership roles with several of the largest retained physician recruiting firms in the country. He is a former President of the National Association of Physician Recruiters (NAPR) and is a sought after speaker and trainer on physician recruitment processes and trends. He has also received accolades from respected healthcare organizations and associations such as: TEAMHealth, Tenet Healthcare, Piedmont Healthcare, Memorial Hermann Hospital, UT Chattanooga, Medical College of Georgia, Physician Hospitals of America, American Academy of Private Physicians, Concierge Medicine Today Forum. Some of his media credits include: NBC News, New England Journal of Medicine, Becker's Healthcare, Neurology Today, MGMA, NAMPC, Concierge Medicine Today, NAPR, and AAPPR (formerly ASPR). ATHENIC GROUP 220 N Jeff Davis Dr, Ste 4 Fayetteville, GA 30214 Office: 404-580-3443 cfowler@athenicgroup.com Recruitment Services Our recruitment services division functions as a boutique search firm specializing in physician and provider recruitment. We use the same resources large retained firms' use, but we take a more tailored and personal approach. Training & Development Our training and development division offers a range of services to help improve your recruitment team's performance, therefore decreasing your need for outsourced recruitment. Services range from skills evaluation, rookie recruiter training, team development, training workshops and ongoing coaching. Complementary Services Our primary focus is to help your practice, facility and community by improving the lives of those who seek healthcare from you. Other complementary services that we offer include: Expert Marketing Services, Succession Planning/Consulting for the Concierge and Direct Primary Care Practice, Expert Witness Testimony Services, and Search Evaluation & Consultation Services. www.AthenicGroup.com © Concierge Medicine Today, LLC. ("CMT") All rights reserved.   Disclaimers: This content is for educational purposes only and does not provide medical, financial, legal, or professional advice. Concierge Medicine Today, LLC (CMT) is not liable for errors from guest contributions. Users should consult reliable advisors before making decisions. By using this content, you agree to CMT's Terms and Conditions and Privacy Policy, releasing CMT from liability. CMT may remove content without notice, and guest interviews do not imply endorsement. Users assume all related risks. Thank you.

Send us a textIn this episode of Causes or Cures, Dr. Eeks chats with Dr. Jerry Avorn, a Professor of Medicine at Harvard Medical School, drug safety watchdog, and author of Rethinking Medications: Truth, Power, and the Drugs You Take. If you've ever felt uneasy about the rising cost of prescription drugs, the process or speed by which new meds are approved, or why the side effects list is longer than your grocery receipt, this episode is for you.Dr. Avorn pulls no punches. We talk about:How our current system rewards speed over evidence, and why “accelerated approval” may sound good but can lead to disaster.The rise of drugs approved with weak or surrogate endpoints, yet priced like gold (yep, you still pay full price for half-baked science).Shocking case studies, like the Vioxx heart attack debacle and the controversial Alzheimer's drug Aduhelm.The FDA's evolution from watchdog to lapdog (in some cases).Conflicts of interest.Public funding, private profits: how taxpayer money fuels breakthroughs that we can't afford. (WTF!)And, yes, we talk about the “Do Your Own Research” crowd.Dr. Avorn's mission? Help patients and doctors actually understand what they're taking or prescribing, and what forces are shaping those decisions.Why listen?Because behind every pill is a story, and it's not always the one you're told in the ad with the beach scene and happy jazz flute.Links:Grab the book: Rethinking Medications: Truth, Power, and the Drugs You Take (Simon & Schuster, 2025)Jerry Avorn, MD, is a professor of medicine at Harvard Medical School and a senior internist in the Mass General Brigham health-care system. He built a leading research center at Harvard to study medication use, outcomes, costs, and policies and developed the educational approach of “academic detailing” to provide evidence-based information about medications to prescribers. One of the nation's most highly cited researchers, Dr. Avorn is the author of Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs, and he has written or cowritten over six hundred papers in the medical literature as well as commentaries in the New York Times, The Washington Post, JAMA, and The New England Journal of Medicine.You can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Or Facebook here.Or X.On Youtube.Or TikTok.SUBSCRIBE to her monthly newsletter here! (Now featuring interviews with top experts on health you care about!)Support the show

On this episode of The Jon Gordon Podcast, I sit down with Dr. Samuel Wilkinson from Yale for a truly fascinating and thought-provoking conversation about the intersection of science, faith, and evolution. Dr. Wilkinson shares the journey that inspired his book, Purpose: What Evolution and Human Nature Imply About the Meaning of Our Existence, and together we dig into some of life's deepest questions: Can science and spirituality really go hand in hand? How do evolution and faith both help shape our understanding of human purpose?   We unpack everything from the “dual potential” within human nature, our capacities for both selfishness and sacrificial love, to the mysteries of free will, consciousness, and whether our brains are actually wired to tune into higher frequencies like love, positivity, and connection. We also challenge some big assumptions about the origins of humanity, what really drives our instinct to help others (even at great personal cost), and why strong family bonds are central to both our biology and our society.   If you've ever wondered how science and spirituality might fit together, or questioned whether there's purpose woven into the process of evolution, this conversation is going to open your mind and encourage your spirit. Don't miss it!   About Dr. Samuel Wilkinson, Samuel T. Wilkinson is Associate Professor of Psychiatry at Yale University, where he also serves as Associate Director of the Yale Depression Research Program. He received his MD from Johns Hopkins School of Medicine. His articles have been featured in the New York Times, the Washington Post, and the Wall Street Journal. He has been the recipient of many awards, including Top Advancements & Breakthroughs from the Brain and Behavior Research Foundation; Top Ten Psychiatry Papers by the New England Journal of Medicine, the Samuel Novey Writing Prize in Psychological Medicine ( Johns Hopkins); the Thomas Detre Award (Yale University); and the Seymour Lustman Award (Yale University).   Here's a few additional resources for you… Follow me on Instagram: @JonGordon11 Order my new book 'The 7 Commitments of a Great Team' today! Every week, I send out a free Positive Tip newsletter via email. It's advice for your life, work and team. You can sign up now here and catch up on past newsletters. Join me for my Day of Development! You'll learn proven strategies to develop confidence, improve your leadership and build a connected and committed team. You'll leave with an action plan to supercharge your growth and results. It's time to Create your Positive Advantage. Get details and sign up here. Do you feel called to do more? Would you like to impact more people as a leader, writer, speaker, coach and trainer? Get Jon Gordon Certified if you want to be mentored by me and my team to teach my proven frameworks principles, and programs for businesses, sports, education, healthcare!

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-444 Overview: An estimated 30% of women worldwide are affected by bacterial vaginosis (BV), and although treatment is typically successful, recurrence rates remain high. Traditional strategies, such as treating male partners, have not significantly reduced recurrence. In this episode, we discuss a recent study that used a new approach to partner treatment and review its potential to reduce BV recurrence. Episode resource links: Vodstrcil LA, Plummer EL, Fairley CK, et al. Male-partner treatment to prevent bacterial vaginosis.  The New England Journal of Medicine. 2025; 392 (10): 947-957. doi: 10.1056/NEJMoa2405404. DynaMed: https://www-dynamed-com.umassmed.idm.oclc.org/condition/bacterial-vaginosis-bv#GUID-E1A22CF7-D0AC-4247-B1F8-54D1CD26FC1A Guest: Susan Feeney, DNP, FNP   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com   

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-444 Overview: An estimated 30% of women worldwide are affected by bacterial vaginosis (BV), and although treatment is typically successful, recurrence rates remain high. Traditional strategies, such as treating male partners, have not significantly reduced recurrence. In this episode, we discuss a recent study that used a new approach to partner treatment and review its potential to reduce BV recurrence. Episode resource links: Vodstrcil LA, Plummer EL, Fairley CK, et al. Male-partner treatment to prevent bacterial vaginosis.  The New England Journal of Medicine. 2025; 392 (10): 947-957. doi: 10.1056/NEJMoa2405404. DynaMed: https://www-dynamed-com.umassmed.idm.oclc.org/condition/bacterial-vaginosis-bv#GUID-E1A22CF7-D0AC-4247-B1F8-54D1CD26FC1A Guest: Susan Feeney, DNP, FNP   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com   

Today's solo episode is an urgent call to wake up to the crumbling systems all around us—healthcare, food, energy, water, housing, the environment and start reclaiming our power, one decision at a time. Darin peels back the curtain on how these systems were designed not to serve us, but to profit off our disconnection. But this isn't a rant—it's a roadmap. With grounded action steps, a rallying cry for sovereignty, and heartfelt encouragement, Darin offers a path forward to opt out of the Matrix and build a better reality together.     What You'll Learn: [00:00] Welcome & why this episode is different [02:11] These systems aren't broken they're failing us. Here's what we can do [03:21] Health or disease care? Why the system profits from your sickness [05:22] Micro vs. macro: how real food and policy change go hand-in-hand [08:11] Water: how tap water is filled with toxins and what to do about it [10:34] The dirty truth about power: fires, pollution, and the case for solar [12:59] From fossil fuels to microgrids: the real solutions that are being ignored [14:45] Food as poison: how ultra-processed foods hijack your biology [15:22] Cook at home. Buy local. And why your food choices matter more than ever [16:50] Shelter or sickness? How your home might be silently harming you [17:31] Flame retardants, VOCs, EMFs: what to reduce and how [18:45] Why you should turn off your Wi-Fi at night and use airplane mode [19:43] Healthcare or symptom care? The call for functional medicine and policy change [21:10] The environment is a mirror: species extinction, pollution, and the cost of convenience [22:45] Personal action: the power of conscious consumption and daily decisions [24:23] Take your power back: how to become the CEO of your life [25:27] It's not about complaining, it's about creating a new paradigm [27:04] Final thoughts: this is your invitation to live a SuperLife [28:30] A sneak peek into Darin's upcoming SuperLife community on Patreon     Thank You to Our Sponsor: Therasage: Go to www.therasage.com and use code DARIN at checkout for 15% off     Find More from Darin Olien: Instagram: @darinolien Podcast: SuperLife Website: https://superlife.com Book: Fatal Conveniences     Key Quote: “You are not powerless, no matter who you are. We are the creators. But first, we must see the system. If we don't see it, we don't change anything. Then we must opt out of these systems that are harming us and the environment, and opt into building a new one, one step at a time.”     Join the SuperLife Movement on Patreon: Be the first to get access to Darin's new SuperLife community on Patreon:

Dr. Joseph McCollom and Dr. Ramy Sedhom discuss precision palliative care, a new strategy that aims to align palliative care delivery with patient and caregiver needs instead of diagnosis alone. TRANSCRIPT ADN Podcast Episode 8-22 Transcript: What Is Precision Palliative Care? Rethinking a Care Delivery Problem Dr. Joseph McCollom: Hello and welcome to the ASCO Daily News Podcast. I'm your guest host, Dr. Joseph McCollom. I'm a GI medical oncologist and palliative oncologist at the Parkview Packnett Family Cancer Institute here in Fort Wayne, Indiana. So, the early benefits of palliative care for patients with cancer have been well documented, but there are challenges in terms of bandwidth to how do we provide this care, given the workforce shortages in the oncology field. So today, we'll be exploring a new opportunity known as precision palliative care, a strategy that aims to align care delivery with patient and caregiver needs and not just diagnosis alone. Joining me for this discussion is Dr. Ramy Sedhom. He is the medical director of oncology and palliative care at Penn Medicine Princeton Health and a clinical assistant professor of medicine at the University of Pennsylvania Perelman School of Medicine. Our full disclosures are available in the transcript of this episode.  Dr. Sedhom, it's great to have you on the podcast today. Thank you so much for being here. Dr. Ramy Sedhom: Thank you, Joe. It's a pleasure to be here and lucky me to be in conversation with a colleague and friend. Yes, many of us have heard about the benefits of early palliative care. Trials have shown better quality of life, reduced symptoms, and potentially even improved survival. But as we know, the reality is translating that evidence into practice, which is really, really challenging. So Joe, both you and I know that not every patient can see palliative care, or I'd even argue should see palliative care, but that also means there are still many people with real needs who still fall through the cracks. That's why I'm really excited about today's topic, which we'll be discussing, which is precision palliative care. It's a growing shift in mindset from what's this patient's diagnosis or what's this patient's prognosis, to what matters most for this person in front of me right now and what are their individual care needs. I think, Joe, it's very exciting because the field is moving from a blanket approach to one tailored to meet people where they actually are. Dr. Joseph McCollom: Absolutely, Ramy. And I think from the early days when palliative care was kind of being introduced and trying to distinguish itself, I think one of the first models that came to clinicians' eyes was Jennifer Temel's paper in The New England Journal of Medicine in 2010. And her colleagues had really looked at early palliative care integration for patients with advanced non–small cell lung cancer. And in that era – this is a pre-immunotherapy era, very early targeted therapy era – the overall prognosis for those patients are similar to the population I serve as a GI medical oncologist, pancreatic cancer today. Typically, median overall survival of a year or less. And so, a lot of her colleagues really wanted her to track overall survival alongside quality of life and depression scores as a result of that. And it really was a landmark publication because not only did it show an improvement of quality of life, but it actually showed an improvement of overall survival. And that was really, I think, revolutionary at the time. You know, a lot of folks had talked about if this was a drug, the FDA would approve it. We all in GI oncology laugh about erlotinib, which got an FDA approval for a 2-week overall survival advantage. And so, it really kind of set the stage for a lot of us in early career who had a passion in the integration of palliative care and oncology. And I think a lot of the subsequent ASCO, NCCN, COC, Commission on Cancer, guidelines followed through with that. But I think what we realized is now we're kind of sitting center stage, there's still a lot of resource issues that if we sent a referral to palliative care for every single patient diagnosed with even an advanced cancer, we would have a significant workforce shortage issue. And so, Ramy, I was wondering if you could talk a little bit about how do we help center in on who are the right patients that are going to have the greatest benefit from a palliative care specialist intervention? Dr. Ramy Sedhom: Thanks, Joe. Great question. So you mentioned Dr. Temel's landmark 2010 trial published in the New England Journal of Medicine. And it is still a game changer in our field. The results of her work showed not only improved quality of life and mood, but I think very surprisingly at the time, a survival benefit for patients with lung cancer who had received early palliative care. That work, of course, has helped shape national guidelines, as you've shared, and it also helped define early, as within 8 weeks of diagnosis. But unfortunately, there remains a disconnect. So in clinical practice, using diagnosis or stage as the only referral trigger doesn't really match the needs that we see show up. And I think unfortunately, the other part is that approach creates a supply demand mismatch. We end up either referring more patients than palliative care teams can handle, or at the opposite extreme, we end up referring no one at all. So, I actually just wanted to quickly give, for example, two real world contrasts. So one center that I actually have friends who work in, tried as a very good quality improvement incentive, auto-refer all patients with stage IV pancreas cancer to palliative care teams. And while very well intentioned, they saw very quickly that in a two-month period, they had 30 new referrals. And on the palliative care side, there were only 15 available new patient slots. On the other hand, something that I often see in practice, is a situation where, for example, consider the case of a 90-year-old with a low-grade B-cell lymphoma. On paper, low-risk disease, but unfortunately, when you look under the microscope, this gentleman is isolated, has symptoms from his bulky adenopathy, and feels very overwhelmed by many competing illnesses. This is someone who, of course, may benefit from palliative care, but probably doesn't check the box. And I think this is where the model of precision palliative care steps in. It's not really about when was someone diagnosed or what is the prognosis or time-based criteria of their cancer, but it's really fundamentally asking the question of who needs help, what kind of help do they need, and how urgently do we need to provide this help? And I think precision palliative care really mirrors the logic and the philosophy of precision oncology. So just like we've made strides trying to match therapies to tumor biology, we also need to have the same attention and the same precision to match support to symptoms, to context of a patient situation and their caregiver, and also to their personal goals. So I think instead of a blanket referral, we really need to tailor care, the right support at the right moment for the right person to the right care teams. And I think to be more precise, there's really four core elements to allow us to do this well. So first, we really need to implement systematic screening. Let's use what we already have. Many of our centers have patient reported outcomes. The Commission on Cancer motivates us to use distress screening tools. And the EHR is there, but we do very little to flag and to surface unmet care needs. We have seen amazing work from people like Dr. Ethan Bash, who is the pioneer on patient-reported outcomes, and Dr. Ravi Parikh, who used to be my colleague at Penn, now at Emory, who show that you could use structured data and machine learning to identify some of these patient needs in real time. The second piece is after a systematic screening, we really need to build very clear referral pathways. One very good example is what the supportive care team at MD Anderson has done, of course, led by Dr. Eduardo Brera and Dr. David Huey, where they have, for example, designed condition-specific triggers. Urgent referrals, for example, to palliative care for severe symptoms, where they talk about it like a rapid response team. They will see them within 72 hours of the flag. But at the same time, if the unmet need is a caregiver distress, perhaps the social work referral is the first part of the palliative care intervention that needs to be placed. And I think this helps create both clarity and consistency but also it pays attention to that provider and availability demand mismatch. Third, I really think we need to triage smartly. As mentioned in the prior example, not every patient needs every team member of the palliative care team. Some benefit most from the behavioral health intervention. Others might benefit from chaplaincy or the clinician for symptom management. And I think aligning intensity with complexity helps us use our teams wisely. Unfortunately, the greatest barrier in all of our health care systems is time and time availability. And I think this is one strategic approach that I have not yet seen used very wisely. And fourth, I really think we need to embrace interdisciplinary care and change our healthcare systems to focus more on value. So this isn't about more consults or RVUs. I think it's really about leveraging our team strengths. Palliative care teams or supportive care teams usually are multidisciplinary in their core. They often have psychologists, social workers, sometimes they have nurse navigators. And I think all of these are really part of that engine of whole person care. But unfortunately, we still are not set up in care delivery systems that unfortunately to this day still model fee for service where the clinician or the physician visit is the only quote unquote real value add. Hopefully as our healthcare systems focus more on delivery and on value, this might help really embrace the structure to bring through the precision palliative care approach. Dr. Joseph McCollom: No, I love those points. You know, we talk frequently in the interdisciplinary team about how a social worker can spend 5 minutes doing something that I could not as a physician spend an hour doing. But does every patient need every member every time? And how do we work as a unified body to deliver that dose of palliative care, specialized palliative care to those right patients and match them? And I think that perfect analogy is in oncology as a medical oncologist, frequently I'm running complex next-generation sequencing paneling on patients' tumors, trying to find out is there a genetic weakness? Is there a susceptibility to a targeted therapy or an immunotherapy so that I can match and do that precision oncology, right patient to the right drug? Similarly, we need to continue to analyze and find these innovative ways like you've talked about, PROs, EHR flags, machine learning tools, to find those right patients and match them to the right palliative care interdisciplinary team members for them. I know we both get to work in oncology spaces and palliative and supportive spaces in our clinical practice. Share a little bit, if you could, Ramy, about what that looks like for your practice. How do you find those right patients? And how do you then intervene with that right palliative oncology dose? Dr. Ramy Sedhom: So Joe, when I first started in this space as a junior faculty, one thing became immediately clear. I think if we rely solely on physicians to identify the patients for palliative care, we're unfortunately going to be very limited by what we individually, personally observe. And I think that's what reflects the reality that many patients have real needs that go unseen. So over the past few years, I've really worked with a lot of my colleagues to really work the health system to change that. The greatest partnership I've personally had has been working with our informatics team to build a real time EHR integrated dashboard that I think helps us give us a broader view of patient needs. What we really think of as the population health perspective. Our dashboard at Penn, for example, pulls in structured data like geriatric assessment results, PHQ-4 screens, patient reported outcomes, whether or not they've been hospitalized, whether or not these hospitalizations are frequent and recurrent. And I think it's allowed us to really move from a reactive approach to one that's more proactive. So let me give you a practical example. So we have embedded in our cancer care team, psycho-oncologists. They share the same clinic space, they're right down the hall. And we actually use this shared dashboard to review weekly trends in distress scores and patient reported outcomes. And oftentimes, if they see a spike in anxiety or worsening symptoms like depression, they'll reach out to me and say, “Hey, I noticed Mrs. Smith reported feeling very anxious today. Do you think it'd be helpful if I joined you for her visit?” And I think that's how we could really use data and teamwork to offer and maximize the right support at the right time. Like many of our other healthcare systems, we also have real-time alerts for hospitalizations. And I think like Dr. Temel's most recent trial, which we'll discuss at some point, I'm sure, it's another key trigger for vulnerability. I think whenever someone's admitted or discharged, we try to coordinate with our palliative care colleagues to assess do they need follow-up and in what timeline. And we know that these are common triggers, progression of disease, hospitalizations, drops in quality-of-life. And it's actually surprisingly simple to implement once you set up the right care structures. And I think these systems don't just help patients, which is what I quickly learned. They also help us as clinicians too. Before we expanded our team, I often felt this weight, especially as someone dual trained in oncology and palliative medicine, as trying to be everything to everyone. I remember one patient in particular, a young woman with metastatic breast cancer who was scheduled for a routine pre-chemo visit with me. Unfortunately, on that day, she had a very dramatic change in function. We whisked her down to x-ray and it revealed a pretty large pathologic fracture in her femur. And suddenly what was scheduled as a 30-minute visit became a very complex conversation around prognosis, urgent need for surgery and many, many life changes. And when I looked at my Epic list, I had a full waiting room. And thankfully, because we have embedded palliative care in our team, I was able to bring in Dr. Collins, the physician who I work with closely, immediately. She spent the full hour with the patient while I was able to continue seeing other patients that morning. And I think that's what team-based care makes possible. It's not just more hands on deck but really optimizing the support the patient needs on each individual day. And I think last, we're also learning a lot from behavioral science. So many institutions like Penn, Stanford, Massachusetts General, they've experimented with a lot of really interesting prompts in the EHR. One of them, for example, is the concept of nodes or the concept of prompt questions. Like, do you think this patient would benefit from a supportive care referral? And I think these low-level nudges, in a sense, can actually really dramatically increase the uptake of palliative care because it makes what's relevant immediately salient and visible to the practicing physician. So I think the key, if I had to maybe finish off with a simple message: It's not flashy tech, it's not massive change against staffing, but it's having a local champion and it's working smarter. It's asking the questions of how can we do this better and setting up the systems to make them more sustainable. Dr. Joseph McCollom: I appreciate you talking about this because I think a lot of folks want to put the wheels on in some way and they don't know where to get started. And so I think some of the models that you've been able to create, being able to track patients, screen your population, find the right individuals, and then work within that team to be able to extend, I think when you have an embedded palliative care specialist in your clinic, they expand your practice as a medical oncologist. And so you can make that warm handoff. And that patient and that caregiver, when they view the experience, they don't view you as a medical oncologist, someone else as a palliative care specialist, they view that team approach. And they said, "The team, my cancer team took care of me." And I think we can really harness a lot of the innovative technological advancements in our EHR to be able to prompt us in this work. I know that Dr. Temel had kind of set the stage for early palliative care intervention, and you did mention her stepped palliative care trial. Where do you see some of the future opportunities as we continue to push the needle forward as oncologists and palliative care specialists? What do you see as being the next step? Dr. Ramy Sedhom: So for those who are not familiar with the stepped palliative care trial, again, work by Dr. Temel, I think it's really important to explain not just the study itself, but I think more importantly, what it's representing for the future of our field. First, I really want to acknowledge Dr. Temel, who is a trailblazer in palliative oncology. Her work has not only shaped how we think about timing and delivery, but really about the value of supportive care. And more importantly, I think for all the young trainees listening, she had shown that rigorous randomized trials in palliative care are possible and meaningful. And I think for me, one quick learning point is that you could be an oncologist and lead this impactful research. And she's inspired many and many of us. Now let's quickly transition to her study. So in this trial, the stepped palliative care trial, patients with advanced lung cancer were randomized into two groups. One group followed the model from her landmark 2010 New England Journal of Medicine paper, which was structured monthly palliative care visits, again, within eight weeks of diagnosis. The second group, which is in this study, the intervention or the stepped palliative care group, received a single early palliative care visit. Think of this as a meet and greet. And then care was actually stepped up. If one of three clinical triggers happened. One, a decline in patient reported quality of life as measured by PROs. Two, disease progression, or three, hospitalization. And the findings which were presented at ASCO 2024 were striking. Clinical outcomes, very similar between the two groups. And this included quality-of-life, end-of-life communication, and resource use. But I think the take-home point is that the number of palliative care visits in the stepped group was significantly lower. So in other words, same impact and fewer visits. This was a very elegant example of how we can model precision palliative care, right sizing patient care based on patient need. So where do we go from here? I think if we want this model to take root nationally, we really need to pull on three key levers: healthcare systems, healthcare payment, and healthcare culture. So from a system alignment, unfortunately, as mentioned too often, the solution to gaps in palliative care is we need more clinicians. And while yes, that's partly true, it's actually not the full picture. I think what we first need to do and what's more likely to be achieved is to develop systems that focus on building the infrastructure that maximizes the reach of our existing care teams. So this means investing in nurse navigation, real-time dashboards with patient-reported outcomes and EHR flags, and again, matching triage protocols where intensity matches complexity. And the goal, as mentioned, isn't to maximize consults, but to really maximize deployment of expertise based on need. The second piece is, of course, we need payment reform. So the stepped palliative care model only works when it allows continuous patient engagement. But unfortunately, current pay models don't reward or incentivize that. In fact, electronic PROs require a very high upfront financial investment and ongoing clinician time with little to no reimbursement. Imagine if we offered bundled payments or value-based incentives for teams that integrated PROs. Or imagine if we reimbursed palliative care based on impact or infrastructure instead of just fee-for-service volume. There is a lot of clear evidence that tele-palliative care is effective. In fact, it was the Plenary at ASCO 2024. Yet we're still battling these conversations around inconsistent reimbursement, and we're always waiting on whether or not telehealth waivers are gonna continue. So I think most importantly is we really need to recognize the broader scope of what palliative care offers, which is caregiver support, improving navigation, coordinating very complex transitions. To me, and what I've always prioritized as a champion at Penn, is that palliative care is not a nice to have, and neither are all of these infrastructures, but they're really essential to whole person care, and they need to be financially supported. And last, we really need a culture shift. We need to change from how palliative care is perceived, and it can't be something other. It can't be something outside of oncology, but it really needs to be embraced as this is part of cancer care itself. I often see hesitancy from many oncologists about introducing palliative care early. But it doesn't need to be a dramatic shift. I think small changes in language, how we introduce the palliative care team, and co-management models can really go a very long way in normalizing this part of patient care. And I'm particularly encouraged, Joe, by one particular innovation in this space, which is really the growth of many startups. And one startup, for example, is Thyme Care, where I've seen them working with many, many private practices across the country, alongside partnerships with payers to really build tech-enabled navigation that tries to basically maximize triage support with electronic PROs. And to me, I really think these models can help scale access without overwhelming current care teams. So precision palliative care, Joe, in summary, I think should be flexible, scalable, and really needs to align based on what patients need. Dr. Joseph McCollom: No, I really appreciate, Ramy, you talking about that it really takes a village to get oncology care in both a competent and a compassionate way. And we need buy-in champions at all levels: the system level, the administrative level, the policy level, the tech level. And we need to change culture. I kind of want to just get your final impressions and also make sure that we make our listeners aware of our article. We should be able to have this in the show notes here as well to find additional tools and resources, all the studies that were discussed in today's episode. But, Ramy, what are some of your kind of final takeaways and conclusions? Dr. Ramy Sedhom: Before we wrap up, I just want to make sure we highlight a very exciting opportunity for residents considering a future in oncology and palliative medicine. Thanks to the leadership of Dr. Jamie Von Roen, who truly championed this cause, ASCO and the ABIM (American Board of Internal Medicine) have partnered to create the first truly integrated palliative care oncology fellowship. Trainees can now double board in just two years or triple board in three with palliative care, oncology, and hematology. And I think, Joe, as you and I both know, it's incredibly rewarding and meaningful to work at this intersection. To close our message, if there's one message I think listeners should carry with them, it's that palliative care is about helping people live as well as possible for as long as possible. And precision palliative care simply helps us do that better. We need to really develop systems that tailor support to individual need, value, and individual goals. Just like our colleagues in precision oncology mentioned, getting the right care to the right patient at the right time, and I would add in the right way. For those who want to learn more, I encourage you to read our full article in JCO, which is “Precision Palliative Care As a Pragmatic Solution for a Care Delivery Problem.” Joe, thank you so, so much for this thoughtful conversation and for your leadership in our field. And thank you to everyone for listening. Thank you all for being champions of this essential part of cancer care. If you haven't yet joined the ASCO Palliative Care Communities of Practice, membership is free, and we'd love to have you. Dr. Joseph McCollom: Thank you, Ramy, not only for sharing your insights today, but the pioneering work that you have done in our field. You are truly an inspiration to me in clinical practice, and it is an honor to call you both a colleague and friend.  And thank you for our listeners for joining us today. If you value the insights that you've heard on the ASCO Daily News Podcast, please subscribe, rate, and review wherever you get your podcasts. Thanks again. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:   Dr. Joseph McCollom @realbowtiedoc Dr. Ramy Sedhom @ramsedhom Follow ASCO on social media:   @ASCO on X (formerly Twitter) ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn   Disclaimer: Dr. Joseph McCollom: No relationships to disclose Dr. Ramy Sedhom: No relationships to disclose

On appelle «médiation animale» ou «zoothérapie» le fait d'intégrer l'animal au parcours de soins du patient. Mise en place pour la première fois dans une unité psychiatrique à l'Université d'État d'Ohio en 1977, la zoothérapie peut permettre de réduire le stress, l'anxiété et la dépression, et de réduire l'isolement social. Dans quel cadre cet accompagnement peut-il être bénéfique pour le patient ? Quels sont les bienfaits de cette thérapie pour le patient et son traitement ? Isabelle Fromantin, infirmière et docteure en sciences. Responsable de l'unité « plaies et cicatrisation » de l'Institut Curie à Paris. Co-auteure de l'ouvrage Snoopy, un chien qui fait du bien, aux éditions Solar  Ermelinda Hadey, infirmière-zoothérapeute de l'Unité fonctionnelle de zoothérapie de l'EPS de Ville-Évrard, en Seine-Saint-Denis, en région parisienne, et créatrice de l'association « les Z'amis de Nono » Elodie, patiente de l'EPS de Ville-Évrard et bénévole de l'association « les Z'amis de Nono ». Un reportage de Raphaëlle Constant. ► En fin d'émission, nous parlons de la plus importante épidémie de diphtérie qu'ait connue l'Europe occidentale depuis 70 ans, selon une étude parue dans le New England Journal of Medicine. Interview du Pr Sylvain Brisse, responsable du Centre national de la diphtérie et responsable de l'Unité biodiversité et épidémiologie des bactéries pathogènes à l'Institut Pasteur.  Programmation musicale :  ► Queen – Cool cat  ► Daara J family – Cosaan.

On appelle «médiation animale» ou «zoothérapie» le fait d'intégrer l'animal au parcours de soins du patient. Mise en place pour la première fois dans une unité psychiatrique à l'Université d'État d'Ohio en 1977, la zoothérapie peut permettre de réduire le stress, l'anxiété et la dépression, et de réduire l'isolement social. Dans quel cadre cet accompagnement peut-il être bénéfique pour le patient ? Quels sont les bienfaits de cette thérapie pour le patient et son traitement ? Isabelle Fromantin, infirmière et docteure en sciences. Responsable de l'unité « plaies et cicatrisation » de l'Institut Curie à Paris. Co-auteure de l'ouvrage Snoopy, un chien qui fait du bien, aux éditions Solar  Ermelinda Hadey, infirmière-zoothérapeute de l'Unité fonctionnelle de zoothérapie de l'EPS de Ville-Évrard, en Seine-Saint-Denis, en région parisienne, et créatrice de l'association « les Z'amis de Nono » Elodie, patiente de l'EPS de Ville-Évrard et bénévole de l'association « les Z'amis de Nono ». Un reportage de Raphaëlle Constant. ► En fin d'émission, nous parlons de la plus importante épidémie de diphtérie qu'ait connue l'Europe occidentale depuis 70 ans, selon une étude parue dans le New England Journal of Medicine. Interview du Pr Sylvain Brisse, responsable du Centre national de la diphtérie et responsable de l'Unité biodiversité et épidémiologie des bactéries pathogènes à l'Institut Pasteur.  Programmation musicale :  ► Queen – Cool cat  ► Daara J family – Cosaan.

Dr. Shuvro Roy talks with Dr. Daniel Blockmans about the efficacy and safety of upadasatinib as a treatment option for giant-cell arteritis.  Read the related article in The New England Journal of Medicine.  Disclosures can be found at Neurology.org. 

We're diving into the top functional and conventional tests to consider after the second trimester or late pregnancy loss, especially if you've been diagnosed with low AMH, high FSH, diminished ovarian reserve (DOR), or premature ovarian insufficiency (POI). If you've had a second trimester loss or late pregnancy loss after 20 weeks and been told “everything looks normal,”this episode is for you. We dive into what's often overlooked in conventional care and how a functional fertility approach can help uncover underlying imbalances that impact conception, hormone health, and pregnancy outcomes. In this episode we cover 7 categories of testing to consider after late loss especially if you have low AMH, diminished ovarian reserve, autoimmune issues, recurrent miscarriage, or unexplained infertility. You'll learn: The top clotting and thrombophilia markers to test (including Factor V Leiden and antiphospholipid antibodies) Which inflammatory and immune markers (hs-CRP, ANA, cytokines, NK cells) are often missed and why they matter How the vaginal microbiome and hidden infections like ureaplasma can cause second-trimester loss The role of chronic stress, adrenal hormones and the HPA axis in pregnancy outcomes Why a comprehensive blood chemistry panel can reveal nutrient deficiencies and hormone imbalances that are missed by conventional labs Key methylation and genetic SNPs (like MTHFR) that impact detoxification, clotting and hormone metabolism The impact of gut health and stool testing on immune tolerance, estrogen balance and inflammation We'll also explain how this whole body functional lens can guide your next steps in preconception planning, whether you're trying again naturally or preparing for IVF. This episode is for you if: You've experienced a loss after 14 weeks of pregnancy and are seeking deeper understanding and support. You want to explore both conventional and functional medicine approaches to uncover underlying causes. You're looking for practical lifestyle, testing, and healing strategies to improve future pregnancy outcomes. --- TIMESTAMPS [00:00:00] Introduction: Late term pregnancy loss overview, compassion, and what to expect in this episode [00:02:30] Functional fertility testing for late term loss thrombophilia panel, immune markers, inflammation, and infections [00:06:00] Stress hormones, nervous system support, and comprehensive blood chemistry for improving pregnancy outcomes [00:09:00] Blood sugar, insulin, and comprehensive thyroid testing in pregnancy loss [00:12:00] Genetic testing, including MTHFR mutations and the importance of body healing before conception [00:14:30] Role of gut health, infections, and estrogen metabolism in pregnancy loss --- RESOURCES

Have you ever wondered what happens when a toddler gets into something they definitely shouldn't? Today, Dr. Monica Gray, Dr. Pradip Kamat, and Dr. Rahul Damania discuss the case of an 18-month-old boy who accidentally ingested concentrated bleach, presenting with stridor, drooling, and vomiting. They review the clinical approach to caustic ingestions in children, including airway management, diagnostic workup, and the roles of endoscopy, steroids, and multidisciplinary care. The episode also highlights potential complications such as esophageal strictures and cancer, emphasizes prevention strategies, and provides key takeaways for intensivists managing similar pediatric emergencies. If you're an intensivist or just want to know what to do in a pediatric emergency, don't miss these essential takeaways for managing one of the scariest situations in the ER.Show Highlights:Case study of an 18-month-old boy who ingested concentrated bleachClinical presentation including symptoms like stridor, drooling, and vomitingManagement strategies for caustic ingestions in childrenImportance of airway management and monitoring in cases of caustic ingestionDiagnostic workup including imaging and endoscopyDifferential diagnosis considerations for similar presentations (e.g., button batteries, laundry detergent pods)Mechanism of injury caused by alkaline substances like bleachLong-term complications associated with caustic ingestions, such as esophageal strictures and cancerMultidisciplinary approach to treatment involving various medical specialtiesPrevention strategies to reduce the incidence of accidental caustic ingestions in childrenReferences:American Academy of Pediatrics – Pediatric Care Online: Esophageal Caustic Injury (AAP clinical guidance on caustic ingestions).Fuhrman & Zimmerman's Pediatric Critical Care textbook – Chapters on toxicology and gastrointestinal emergencies (covering caustic injury management and critical care approach).Hoffman RS, et al. “Ingestion of Caustic Substances.” New England Journal of Medicine. 2020; 382(18):1739-1748. A comprehensive review of caustic ingestion injuries and management.Arnold M, Numanoglu A. “Caustic ingestion in children – a review.” Semin Pediatr Surg. 2017;26(2):95-104. Review of epidemiology, pathophysiology, and treatment of caustic injuries in kids.Johnson CM, Brigger MT. “The public health impact of pediatric caustic ingestion injuries.” Arch Otolaryngol Head Neck Surg. 2012;138(12):1111-1115. (Epidemiology study showing declining incidence).Pediatric Critical Care Medicine (PCCM) Journal – various case reports and series on caustic ingestion (for case-based insights), and annual National Poison Data System reports (for statistics on pediatric poisonings).Tringali A, et al. ESGE/ESPGHAN Pediatric GI Endoscopy Guidelines (Endoscopy, 2017) – Includes recommendations for endoscopy timing and steroid use in caustic ingestions.Usta M, et al. “High doses of methylprednisolone in the management of caustic esophageal burns.” Pediatrics. 2014;133(6):E1518-24. (Key study demonstrating steroids benefit in grade 2b injuries).Royal Children's Hospital Melbourne – Clinical Practice Guidelines: Caustic Ingestions (2019) – Practical hospital guidelines emphasizing early intubation for airway threat, endoscopy within 24h, IV PPI, and supportive care.

Welcome to PsychEd, the psychiatry podcast for medical learners, by medical learners.This short episode is about an approach to patients with psychotic symptoms.Hosts: Ravi Bhindi (CC3), Dr. Angad Singh (PGY2)Audio editing: Dr. Angad Singh (PGY2)Show notes: Dr. Angad Singh (PGY2)Infographic: Dr. Kate BraithwaiteReferences:Griswold, K. S., Del Regno, P. A., & Berger, R. C. (2015). Recognition and differential diagnosis of psychosis in primary care. American family physician, 91(12), 856-863.Hua, L. L., Alderman, E. M., Chung, R. J., Grubb, L. K., Lee, J., Powers, M. E., ... & Wallace, S. B. (2021). Collaborative care in the identification and management of psychosis in adolescents and young adults. Pediatrics, 147(6), e2021051486.Lieberman, J. A., & First, M. B. (2018). Psychotic disorders. New England Journal of Medicine, 379(3), 270-280.PsychDB. (2021, Jan 15). Psychotic Disorders. Retrieved July 15, 2025, from https://www.psychdb.com/psychosis/homePsychDB. (2022, Jan 26). Psychotic Depression. Retrieved July 15, 2025, from https://www.psychdb.com/mood/1-depression/psychoticPsychDB. (2021, Jan 15). Psychotic Disorders. Retrieved July 15, 2025, from https://www.psychdb.com/psychosis/homeResources:https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/psychosishttps://www.earlypsychosis.ca/symptoms-of-psychosis/For more PsychEd, follow us on Instagram (@psyched.podcast),  Facebook (PsychEd Podcast), and X (@psychedpodcast). You can email us at psychedpodcast@gmail.com and visit our website at psychedpodcast.org.

The incidence of early onset colorectal cancer (EOCRC) has been rising prompting the change in change in screening guidelines to 45 years of age for average risk patients. Join us for an in-depth discussion with guest speakers Dr. Andrea Cercek and Dr. Nancy You, where we provide a comprehensive look at the growing challenge of EOCRC. Hosts: - Dr. Janet Alvarez - General Surgery Resident at New York Medical College/Metropolitan Hospital Center - Dr. Wini Zambare – General Surgery Resident at Weill Cornell Medical Center/New York Presbyterian - Dr. Phil Bauer, Graduating Colorectal Surgical Oncology Fellow at Memorial Sloan Kettering Cancer Center  - Dr. J. Joshua Smith MD, PhD, Chair, Department of Colon and Rectal Surgery at MD Anderson Cancer Center - Dr. Andrea Cercek - Gastrointestinal Medical Oncologist at Memorial Sloan Kettering Cancer Center - Dr. Y. Nancy You, MD MHSc - Professor, Department of Colon and Rectal Surgery at MD Anderson Cancer Center Learning objectives:  - Describe trends in incidence of colorectal cancer, with emphasis on the rise of EOCRC. - Identify age groups and demographics most affected by EOCRC. - Summarize USPSTF recommendations for colorectal cancer screening. - Distinguish between screening methods (e.g., colonoscopy, FIT-DNA) and their sensitivity. - Understand treatment approaches for colon and rectal cancer (CRC) - Understand the role of mismatch repair (MMR) status in guiding treatment. - Outline the importance of genetic counseling and testing in young patients. - Discuss racial, ethnic, and socioeconomic disparities in CRC incidence and outcomes. - Describe the impact of cancer treatment on fertility and sexual health. -  Review fertility preservation options. - Identify the value of integrated care teams for young CRC patients. References: 1.         Siegel, R. L. et al. Colorectal Cancer Incidence Patterns in the United States, 1974–2013. JNCI J. Natl. Cancer Inst. 109, djw322 (2017). https://pubmed.ncbi.nlm.nih.gov/28376186/ 2.         Abboud, Y. et al. Rising Incidence and Mortality of Early-Onset Colorectal Cancer in Young Cohorts Associated with Delayed Diagnosis. Cancers 17, 1500 (2025). https://pubmed.ncbi.nlm.nih.gov/40361427/ 3.         Phang, R. et al. Is the Incidence of Early-Onset Adenocarcinomas in Aotearoa New Zealand Increasing? Asia Pac. J. Clin. Oncol.https://pubmed.ncbi.nlm.nih.gov/40384533/ 4.         Vitaloni, M. et al. Clinical challenges and patient experiences in early-onset colorectal cancer: insights from seven European countries. BMC Gastroenterol. 25, 378 (2025). https://pubmed.ncbi.nlm.nih.gov/40375142/ 5.         Siegel, R. L. et al. Global patterns and trends in colorectal cancer incidence in young adults. (2019) doi:10.1136/gutjnl-2019-319511. https://pubmed.ncbi.nlm.nih.gov/31488504/ 6.         Cercek, A. et al. A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. J. Natl. Cancer Inst. 113, 1683–1692 (2021). https://pubmed.ncbi.nlm.nih.gov/34405229/ 7.         Zheng, X. et al. Comprehensive Assessment of Diet Quality and Risk of Precursors of Early-Onset Colorectal Cancer. JNCI J. Natl. Cancer Inst. 113, 543–552 (2021). https://pubmed.ncbi.nlm.nih.gov/33136160/ 8.         Standl, E. & Schnell, O. Increased Risk of Cancer—An Integral Component of the Cardio–Renal–Metabolic Disease Cluster and Its Management. Cells 14, 564 (2025). https://pubmed.ncbi.nlm.nih.gov/40277890/ 9.         Muller, C., Ihionkhan, E., Stoffel, E. M. & Kupfer, S. S. Disparities in Early-Onset Colorectal Cancer. Cells 10, 1018 (2021). https://pubmed.ncbi.nlm.nih.gov/33925893/ 10.       US Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 325, 1965–1977 (2021). https://pubmed.ncbi.nlm.nih.gov/34003218/ 11.       Fwelo, P. et al. Differential Colorectal Cancer Mortality Across Racial and Ethnic Groups: Impact of Socioeconomic Status, Clinicopathology, and Treatment-Related Factors. Cancer Med. 14, e70612 (2025). https://pubmed.ncbi.nlm.nih.gov/40040375/ 12.       Lansdorp-Vogelaar, I. et al. Contribution of Screening and Survival Differences to Racial Disparities in Colorectal Cancer Rates. Cancer Epidemiol. Biomarkers Prev. 21, 728–736 (2012). https://pubmed.ncbi.nlm.nih.gov/22514249/ 13.       Ko, T. M. et al. Low neighborhood socioeconomic status is associated with poor outcomes in young adults with colorectal cancer. Surgery 176, 626–632 (2024). https://pubmed.ncbi.nlm.nih.gov/38972769/ 14.       Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A. & Jemal, A. Colorectal cancer statistics, 2023. CA. Cancer J. Clin. 73, 233–254 (2023). https://pubmed.ncbi.nlm.nih.gov/36856579/ 15.       Jain, S., Maque, J., Galoosian, A., Osuna-Garcia, A. & May, F. P. Optimal Strategies for Colorectal Cancer Screening. Curr. Treat. Options Oncol. 23, 474–493 (2022). https://pubmed.ncbi.nlm.nih.gov/35316477/ 16.       Zauber, A. G. The Impact of Screening on Colorectal Cancer Mortality and Incidence: Has It Really Made a Difference? Dig. Dis. Sci. 60, 681–691 (2015). https://pubmed.ncbi.nlm.nih.gov/25740556/ 17.       Edwards, B. K. et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116, 544–573 (2010). https://pubmed.ncbi.nlm.nih.gov/19998273/ 18.       Cercek, A. et al. Nonoperative Management of Mismatch Repair–Deficient Tumors. New England Journal of Medicine 392, 2297–2308 (2025). https://pubmed.ncbi.nlm.nih.gov/40293177/ 19.       Monge, C., Waldrup, B., Carranza, F. G. & Velazquez-Villarreal, E. Molecular Heterogeneity in Early-Onset Colorectal Cancer: Pathway-Specific Insights in High-Risk Populations. Cancers 17, 1325 (2025). https://pubmed.ncbi.nlm.nih.gov/40282501/ 20.       Monge, C., Waldrup, B., Carranza, F. G. & Velazquez-Villarreal, E. Ethnicity-Specific Molecular Alterations in MAPK and JAK/STAT Pathways in Early-Onset Colorectal Cancer. Cancers 17, 1093 (2025). https://pubmed.ncbi.nlm.nih.gov/40227607/ 21.       Benson, A. B. et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. JNCCN 19, 329–359 (2021). https://pubmed.ncbi.nlm.nih.gov/33724754/ 22.       Christenson, E. S. et al. Nivolumab and Relatlimab for the treatment of patients with unresectable or metastatic mismatch repair proficient colorectal cancer. https://pubmed.ncbi.nlm.nih.gov/40388545/ 23.       Dasari, A. et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. The Lancet 402, 41–53 (2023). https://pubmed.ncbi.nlm.nih.gov/37331369/ 24.       Strickler, J. H. et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 24, 496–508 (2023). https://pubmed.ncbi.nlm.nih.gov/37142372/ 25.       Sauer, R. et al. Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer. N. Engl. J. Med. 351, 1731–1740 (2004). https://pubmed.ncbi.nlm.nih.gov/15496622/ 26.       Cercek, A. et al. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncol. 4, e180071 (2018). https://pubmed.ncbi.nlm.nih.gov/29566109/ 27.       Garcia-Aguilar, J. et al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J. Clin. Oncol. 40, 2546–2556 (2022). https://pubmed.ncbi.nlm.nih.gov/35483010/ 28.       Schrag, D. et al. Preoperative Treatment of Locally Advanced Rectal Cancer. N. Engl. J. Med. 389, 322–334 (2023). https://pubmed.ncbi.nlm.nih.gov/37272534/ 29.       Kunkler, I. H., Williams, L. J., Jack, W. J. L., Cameron, D. A. & Dixon, J. M. Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer. N. Engl. J. Med. 388, 585–594 (2023). https://pubmed.ncbi.nlm.nih.gov/36791159/ 30.       Jacobsen, R. L., Macpherson, C. F., Pflugeisen, B. M. & Johnson, R. H. Care Experience, by Site of Care, for Adolescents and Young Adults With Cancer. JCO Oncol. Pract. (2021) doi:10.1200/OP.20.00840. https://pubmed.ncbi.nlm.nih.gov/33566700/ 31.       Ruddy, K. J. et al. Prospective Study of Fertility Concerns and Preservation Strategies in Young Women With Breast Cancer. J. Clin. Oncol. (2014) doi:10.1200/JCO.2013.52.8877. https://pubmed.ncbi.nlm.nih.gov/24567428/ 32.       Su, H. I. et al. Fertility Preservation in People With Cancer: ASCO Guideline Update. J. Clin. Oncol. 43, 1488–1515 (2025). https://pubmed.ncbi.nlm.nih.gov/40106739/ 33.       Smith, K. L., Gracia, C., Sokalska, A. & Moore, H. Advances in Fertility Preservation for Young Women With Cancer. Am. Soc. Clin. Oncol. Educ. Book 27–37 (2018) doi:10.1200/EDBK_208301. https://pubmed.ncbi.nlm.nih.gov/30231357/ 34.       Blumenfeld, Z. How to Preserve Fertility in Young Women Exposed to Chemotherapy? The Role of GnRH Agonist Cotreatment in Addition to Cryopreservation of Embrya, Oocytes, or Ovaries. The Oncologist 12, 1044–1054 (2007). 35.       Bhagavath, B. The current and future state of surgery in reproductive endocrinology. Curr. Opin. Obstet. Gynecol. 34, 164 (2022). 36.       Ribeiro, R. et al. Uterine transposition: technique and a case report. Fertil. Steril. 108, 320-324.e1 (2017). 37.       Yazdani, A., Sweterlitsch, K. M., Kim, H., Flyckt, R. L. & Christianson, M. S. Surgical Innovations to Protect Fertility from Oncologic Pelvic Radiation Therapy: Ovarian Transposition and Uterine Fixation. J. Clin. Med. 13, 5577 (2024). 38.       Holowatyj, A. N., Eng, C. & Lewis, M. A. Incorporating Reproductive Health in the Clinical Management of Early-Onset Colorectal Cancer. JCO Oncol. Pract. 18, 169–172 (2022). ***Behind the Knife Colorectal Surgery Oral Board Audio Review: https://app.behindtheknife.org/course-details/colorectal-surgery-oral-board-audio-review Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Dr. Charles LeBaron is a retired CDC scientist and the author of Greed to Do Good: The Untold Story of CDC's Disastrous War on Opioids. He talks with Steve about the ill-considered response to the opioid crisis and the tragic and preventable consequences of the CDC's 2016 guidelines. Restricting prescriptions without providing treatment (whether for pain relief or addiction) drove users to illicit opioids like fentanyl and a surge in overdose deaths.The conversation expands to systemic issues, including the corporate greed of Big Pharma, political exploitation of the crisis, and the punitive rather than rehabilitative approach to addiction. Steve and Charles highlight how austerity policies and privatization exacerbate the epidemic, disproportionately harming working class and marginalized communities. They criticize current political responses, such as RFK Jr.'s proposed cuts to addiction treatment programs in favor of ineffective "healing farms," as emblematic of a broader failure to address root causes. Both emphasize the need for compassionate, science-driven solutions over criminalization, underscoring how public health and social equity are inextricably linked. For more than twenty-eight years, Charles LeBaron worked as a medical epidemiologist at the Centers for Disease Control and Prevention (CDC). While there, he was the author of more than fifty scientific studies published in peer-reviewed journals, including first- or senior- author papers in the New England Journal of Medicine and the Journal of the American Medical Association.